[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFwxhtgukgPJQbdrunACXRKvJsmdB-EtUaomyFyzO9FY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"Montefiore Medical Center",[4],403,false,76,29,497503,53,207,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Asthma",13,{"name":18,"count":19},"Pain",12,{"name":21,"count":22},"Acute Pain",11,{"name":24,"count":22},"Migraine",{"name":26,"count":27},"Low Back Pain",8,{"name":29,"count":30},"Breast Cancer",6,{"name":32,"count":30},"HIV Infections",{"name":34,"count":35},"Hidradenitis Suppurativa",5,[37,42,47,52,56,60,65,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05184842","Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine\u002FVenetoclax in MDS and AML","2023-12-20","Venetoclax",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05500092","An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","2025-07-01","Nivolumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04500899","Use of Phenylephrine for Assessment of Mitral Regurgitation Severity","2026-06","Mydfrin",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT05001750","Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?","Long term (continuous) prophylactic antibiotics",{"nctId":57,"briefTitle":58,"date":50,"intervention":59},"NCT05246267","Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis","Dupilumab",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07076069","The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair","2026-06-01","Multimodal Pain Regimen",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07048769","Paracervical Block for Pain Reduction in Saline Infusion Sonograms","2026-07","Lidocaine",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07228052","Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department","2026-09","Dexamethasone 16mg IM",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06502158","Mifepristone vs Misoprostol","2026-10","Mifepristone",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06450392","The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery","2027-01","Tranexamic acid",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,222,316,397,426,459,495,513,539,557,578,596,619,637,662,680,698,716,734,760,786,825,847,869,893,911,929,976,998,1022,1040,1065,1091,1109,1127,1148,1175,1193,1211,1236,1254,1280,1314,1341,1359,1377,1395,1413,1438,1456,1510,1545,1570,1591,1697,1765,1829,1873,1903,1943,1976,2011,2033,2066,2088,2137,2159,2188,2210,2244,2270,2296,2314,2332,2356,2374,2392,2410,2428,2446,2475,2493,2511,2538,2556,2584,2602,2620,2638,2656,2674,2692,2716,2740,2764,2782,2800,2827,2845,2869,2887,2912,2930,2948,2966,2990,3014,3037,3064,3082,3100,3125,3143,3161,3179,3197,3215,3233,3251,3269,3287,3305,3329,3354,3372,3390,3415,3433,3459,3477,3495,3523,3541,3559,3577,3599,3623,3641,3665,3689,3713,3737,3763,3798,3831,3855,3873,3891,3916,3934,3962,3980,3998,4016,4034,4057,4075,4093,4117,4135,4153,4179,4197,4221,4245,4263,4281,4304,4328,4361,4395,4425,4458,4481,4506,4524,4549,4573,4598,4621,4647,4665,4690,4708,4726,4748,4772,4798,4816,4840,4858,4882,4900,4918,4936,4954,4977,5001,5025,5043,5069,5094,5112,5130,5155,5173,5191,5209,5235,5253,5271,5294,5318,5341,5367,5395,5413,5437,5463,5481,5505,5543,5569,5587,5605,5628,5646,5664,5686,5707,5725,5748,5774,5792,5810,5828,5854,5872,5890,5908,5926,5944,5962,5986,6024,6068,6098,6127,6157,6189,6212,6237,6255,6273,6291,6309,6327,6345,6363,6389,6414,6438,6461,6483,6507,6530,6555,6573,6591,6616],{"intervention":94,"totalTrials":95,"cells":96},"Metoclopramide",10,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":117,"PHASE4":140,"NA":220},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT03056352","Metoclopramide for Post-Traumatic Headache. A Pilot Study","COMPLETED",[87,88],"2017-07-20","2017-08-15","2017-03-01",21,[114],"Post-Traumatic Headache",[94,116],"Diphenhydramine",{"trials":118,"activeCount":99},[119,130],{"nctId":120,"briefTitle":121,"status":107,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT00682734","Metoclopramide for Migraine: A Dose Finding Study",[89],"2010-03","2008-04",349,[24],[128,128,128,129],"metoclopramide","Diphenhydramine 25mg",{"nctId":131,"briefTitle":132,"status":107,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT03220958","Metoclopramide for Post Traumatic Headache",[89],"2020-04-01","2017-08-01",160,[114],[94,116,139],"Normal saline",{"trials":141,"activeCount":219,"soonestReadout":210},[142,154,166,175,185,196,205],{"nctId":143,"briefTitle":144,"status":107,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT01267864","Valproate Versus Ketorolac Versus Metoclopramide",[90],"2013-03","2010-11",330,[150],"Acute Migraine",[94,152,153],"Ketorolac","Valproate",{"nctId":155,"briefTitle":156,"status":107,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT02847494","Corticosteroids for Acute Migraine in the Emergency Department",[90],"2017-09-21","2017-09-30","2016-09-01",220,[24],[128,164,165],"Dexamethasone","methylprednisolone acetate",{"nctId":167,"briefTitle":168,"status":107,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":8,"conditions":172,"interventions":173},"NCT00364806","Prochlorperazine vs Metoclopramide",[90],"2007-03","2006-08",[24],[174,94],"Prochlorperazine",{"nctId":176,"briefTitle":177,"status":107,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"NCT01825941","Diphenhydramine for Acute Migraine",[90],"2014-12","2013-04",208,[24],[128,184],"diphenhydramine",{"nctId":186,"briefTitle":187,"status":107,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT01011673","Metoclopramide Versus Ketorolac for Tension-type Headache",[90],"2012-09","2012-11","2009-11",123,[194],"Headache",[94,152],{"nctId":197,"briefTitle":198,"status":107,"phases":199,"primaryCompletion":200,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":204},"NCT03269435","Greater Occipital Nerve Block Versus Metoclopramide",[90],"2020-03-21","2017-11-01",99,[24],[94],{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":217},"NCT06740812","Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","NOT_YET_RECRUITING",[90],"2027-02","2026-05",212,[214,215,216],"Nausea and Vomiting","Nausea","Vomiting",[218,94],"Fosaprepitant for",1,{"trials":221,"activeCount":99},[],{"intervention":164,"totalTrials":223,"cells":224},7,{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":241,"NA":314},{"trials":226,"activeCount":99},[],{"trials":228,"activeCount":99},[],{"trials":230,"activeCount":99},[],{"trials":232,"activeCount":99},[233],{"nctId":234,"briefTitle":235,"status":107,"phases":236,"primaryCompletion":171,"completion":171,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT00122278","Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines",[89],"2005-07",205,[24],[164],{"trials":242,"activeCount":219,"soonestReadout":306},[243,254,271,275,288,301],{"nctId":244,"briefTitle":245,"status":107,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT04799015","Dexamethasone for Post Traumatic Headache",[90],"2024-11-17","2024-12-22","2021-06-25",162,[114],[164,253],"Metoclopramide 10mg",{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":219,"conditions":261,"interventions":268},"NCT04155008","Nutrition and Pharmacological Algorithm for Oncology Patients Study","TERMINATED",[90],"2021-04-05","2021-03-01",[262,263,264,265,266,267],"Oncologic Complications","Quality of Life","Nutrition Poor","Head and Neck Cancer","Lung Cancer","Pancreatic Cancer",[164,269,270],"Dronabinol","Mirtazapine",{"nctId":155,"briefTitle":156,"status":107,"phases":272,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":273,"interventions":274},[90],[24],[128,164,165],{"nctId":276,"briefTitle":277,"status":257,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":95,"conditions":281,"interventions":283},"NCT02989597","Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients",[90],"2020-11-10","2017-07-29",[282],"Pain, Postoperative",[284,164,285,286,287],"Methadone Hydrochloride","Ketamine","Remifentanil","Sufentanil",{"nctId":289,"briefTitle":290,"status":107,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":298},"NCT02653144","the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block",[90],"2018-11","2018-11-27","2016-03",105,[297],"Opioid Use, Unspecified",[299,300,164],"Ropivacaine","Dexmedetomidine",{"nctId":302,"briefTitle":303,"status":304,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},"NCT05721027","Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.","RECRUITING",[90],"2027-10","2023-07-05",132,[310,311,26],"Radiculopathy, Lumbosacral Region","Back Pain With Radiation",[313,164],"Ibuprofen 400 mg",{"trials":315,"activeCount":99},[],{"intervention":317,"totalTrials":30,"cells":318},"Naproxen",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":338,"NA":395},{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"trials":326,"activeCount":99},[327],{"nctId":328,"briefTitle":329,"status":107,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT02646124","Diazepam Use With Standard Management for Acute Low Back Pain",[88,89],"2016-02","2016-05","2015-06",114,[26],[317,337],"Diazepam",{"trials":339,"activeCount":219,"soonestReadout":366},[340,351,362,373,383],{"nctId":341,"briefTitle":342,"status":107,"phases":343,"primaryCompletion":344,"completion":345,"start":294,"enrollment":346,"conditions":347,"interventions":348},"NCT02665286","Orphenadrine and Methocarbamol for LBP",[90],"2017-04","2017-05",240,[26],[349,350,317],"Orphenadrine","Methocarbamol",{"nctId":352,"briefTitle":353,"status":107,"phases":354,"primaryCompletion":355,"completion":355,"start":170,"enrollment":356,"conditions":357,"interventions":360},"NCT00449787","Comparing Naproxen to Sumatriptan for Emergency Headache Patients",[90],"2009-07",401,[24,358,359],"Tension-type Headache","Primary Headache Disorder",[361,317],"Sumatriptan 100 mg",{"nctId":363,"briefTitle":364,"status":304,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},"NCT05851976","Duloxetine for LBP",[90],"2027-05","2023-10-04",120,[370],"Back Pain, Low",[317,372],"Duloxetine",{"nctId":374,"briefTitle":375,"status":107,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT01071317","Trial of Comprehensive Migraine Intervention",[90],"2012-01","2010-02",50,[24],[317,382],"Sumatriptan",{"nctId":384,"briefTitle":385,"status":107,"phases":386,"primaryCompletion":387,"completion":179,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT01587274","A Randomized Study of Three Medication Regimens for Acute Low Back Pain",[90],"2014-10","2012-04",323,[391],"Acute Low Back Pain",[317,393,394],"Cyclobenzaprine","Oxycodone\u002F acetaminophen",{"trials":396,"activeCount":99},[],{"intervention":313,"totalTrials":398,"cells":399},2,{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":424},{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":99},[],{"trials":405,"activeCount":99},[],{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":219,"soonestReadout":306},[410,420],{"nctId":411,"briefTitle":412,"status":107,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":418},"NCT04611529","Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.",[90],"2023-06-30","2021-03-02",198,[26],[313,419],"Topical diclofenac",{"nctId":302,"briefTitle":303,"status":304,"phases":421,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":422,"interventions":423},[90],[310,311,26],[313,164],{"trials":425,"activeCount":99},[],{"intervention":69,"totalTrials":398,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":457},{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":219,"soonestReadout":68},[438,450],{"nctId":439,"briefTitle":440,"status":107,"phases":441,"primaryCompletion":442,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT03300674","Intravenous Lidocaine Randomized Comparative Effectiveness Trial",[90],"2018-08-16","2018-08-28","2018-01-10",154,[447],"Abdominal Pain",[449,69],"Hydromorphone",{"nctId":66,"briefTitle":67,"status":304,"phases":451,"primaryCompletion":68,"completion":68,"start":452,"enrollment":453,"conditions":454,"interventions":456},[90],"2025-07-02",246,[455],"Pain During Saline Infusion Sonogram",[69],{"trials":458,"activeCount":99},[],{"intervention":84,"totalTrials":398,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":493},{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"trials":466,"activeCount":99},[],{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":219,"soonestReadout":83},[471,482],{"nctId":472,"briefTitle":473,"status":107,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":481},"NCT04947514","Use of Tranexamic Acid in Reduction Mammoplasty",[90],"2022-07-13","2021-10-29",98,[479,480],"Hematoma Postoperative","Venous Thromboembolism",[84],{"nctId":81,"briefTitle":82,"status":304,"phases":483,"primaryCompletion":83,"completion":83,"start":484,"enrollment":485,"conditions":486,"interventions":489},[90],"2024-10-07",150,[487,488],"Orbital Edema","Orbital Ecchymosis",[84,490,491,492],"Tranexamic Acid in NaCl,Iso-Os 1,000 Mg\u002F100 mL","normal saline -","normal saline - intravenous",{"trials":494,"activeCount":99},[],{"intervention":372,"totalTrials":219,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":511},{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":219,"soonestReadout":366},[507],{"nctId":363,"briefTitle":364,"status":304,"phases":508,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":509,"interventions":510},[90],[370],[317,372],{"trials":512,"activeCount":99},[],{"intervention":514,"totalTrials":219,"cells":515},"Acetaminophen 1000mg PO",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":537},{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[],{"trials":525,"activeCount":219,"soonestReadout":530},[526],{"nctId":527,"briefTitle":528,"status":208,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT07595302","Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain",[90],"2027-06-30","2026-07-30",140,[534],"Pelvic Pain",[514,536],"IV Acetaminophen 1000mg",{"trials":538,"activeCount":99},[],{"intervention":536,"totalTrials":219,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":555},{"trials":542,"activeCount":99},[],{"trials":544,"activeCount":99},[],{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":219,"soonestReadout":530},[551],{"nctId":527,"briefTitle":528,"status":208,"phases":552,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":553,"interventions":554},[90],[534],[514,536],{"trials":556,"activeCount":99},[],{"intervention":74,"totalTrials":219,"cells":558},{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":567,"NA":576},{"trials":560,"activeCount":99},[],{"trials":562,"activeCount":99},[],{"trials":564,"activeCount":99},[],{"trials":566,"activeCount":99},[],{"trials":568,"activeCount":219,"soonestReadout":73},[569],{"nctId":71,"briefTitle":72,"status":208,"phases":570,"primaryCompletion":73,"completion":73,"start":571,"enrollment":572,"conditions":573,"interventions":574},[90],"2026-04",182,[15],[74,575],"Prednisone 60mg PO",{"trials":577,"activeCount":99},[],{"intervention":575,"totalTrials":219,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":594},{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":219,"soonestReadout":73},[590],{"nctId":71,"briefTitle":72,"status":208,"phases":591,"primaryCompletion":73,"completion":73,"start":571,"enrollment":572,"conditions":592,"interventions":593},[90],[15],[74,575],{"trials":595,"activeCount":99},[],{"intervention":64,"totalTrials":219,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":617},{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"trials":607,"activeCount":219,"soonestReadout":63},[608],{"nctId":61,"briefTitle":62,"status":304,"phases":609,"primaryCompletion":63,"completion":63,"start":610,"enrollment":611,"conditions":612,"interventions":615},[90],"2025-07-21",130,[613,614],"Rotator Cuff Repairs","Pain Management",[64,616],"Standard of Care Pain Regimen",{"trials":618,"activeCount":99},[],{"intervention":616,"totalTrials":219,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":635},{"trials":622,"activeCount":99},[],{"trials":624,"activeCount":99},[],{"trials":626,"activeCount":99},[],{"trials":628,"activeCount":99},[],{"trials":630,"activeCount":219,"soonestReadout":63},[631],{"nctId":61,"briefTitle":62,"status":304,"phases":632,"primaryCompletion":63,"completion":63,"start":610,"enrollment":611,"conditions":633,"interventions":634},[90],[613,614],[64,616],{"trials":636,"activeCount":99},[],{"intervention":638,"totalTrials":219,"cells":639},"buprenorphine-naloxone",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":660},{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":219,"soonestReadout":654},[650],{"nctId":651,"briefTitle":652,"status":304,"phases":653,"primaryCompletion":654,"completion":530,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT05450718","Low-dose Buprenorphine Initiation for Opioid Use Disorder",[90],"2027-03-17","2024-11-11",70,[658],"Opioid Use Disorder",[638,638],{"trials":661,"activeCount":99},[],{"intervention":490,"totalTrials":219,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":678},{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":99},[],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[],{"trials":673,"activeCount":219,"soonestReadout":83},[674],{"nctId":81,"briefTitle":82,"status":304,"phases":675,"primaryCompletion":83,"completion":83,"start":484,"enrollment":485,"conditions":676,"interventions":677},[90],[487,488],[84,490,491,492],{"trials":679,"activeCount":99},[],{"intervention":491,"totalTrials":219,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":696},{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":99},[],{"trials":691,"activeCount":219,"soonestReadout":83},[692],{"nctId":81,"briefTitle":82,"status":304,"phases":693,"primaryCompletion":83,"completion":83,"start":484,"enrollment":485,"conditions":694,"interventions":695},[90],[487,488],[84,490,491,492],{"trials":697,"activeCount":99},[],{"intervention":492,"totalTrials":219,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":714},{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":219,"soonestReadout":83},[710],{"nctId":81,"briefTitle":82,"status":304,"phases":711,"primaryCompletion":83,"completion":83,"start":484,"enrollment":485,"conditions":712,"interventions":713},[90],[487,488],[84,490,491,492],{"trials":715,"activeCount":99},[],{"intervention":218,"totalTrials":219,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":732},{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":219,"soonestReadout":210},[728],{"nctId":206,"briefTitle":207,"status":208,"phases":729,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":730,"interventions":731},[90],[214,215,216],[218,94],{"trials":733,"activeCount":99},[],{"intervention":735,"totalTrials":219,"cells":736},"DaxibotulinumtoxinA",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":758},{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":219,"soonestReadout":751},[747],{"nctId":748,"briefTitle":749,"status":304,"phases":750,"primaryCompletion":751,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":757},"NCT06195241","Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm",[90],"2027-03","2025-02-11",40,[755,756],"Benign Essential Blepharospasm","Hemifacial Spasm",[735],{"trials":759,"activeCount":99},[],{"intervention":269,"totalTrials":398,"cells":761},{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":778,"NA":784},{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":219,"soonestReadout":774},[770],{"nctId":771,"briefTitle":772,"status":208,"phases":773,"primaryCompletion":774,"completion":774,"start":211,"enrollment":753,"conditions":775,"interventions":776},"NCT07148206","Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial",[89],"2027-12",[658],[269,777],"Epidiolex 100 mg\u002FmL Oral Solution",{"trials":779,"activeCount":99},[780],{"nctId":255,"briefTitle":256,"status":257,"phases":781,"primaryCompletion":259,"completion":259,"start":260,"enrollment":219,"conditions":782,"interventions":783},[90],[262,263,264,265,266,267],[164,269,270],{"trials":785,"activeCount":99},[],{"intervention":787,"totalTrials":398,"cells":788},"Pilocarpine",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":821,"NA":823},{"trials":790,"activeCount":99},[],{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":219,"soonestReadout":814},[797,810],{"nctId":798,"briefTitle":799,"status":800,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":99,"conditions":804,"interventions":807},"NCT04005079","Pilocarpine After Combined Cataract\u002FTrabectome Surgery","WITHDRAWN",[89],"2021-01-21","2019-06-05",[805,806],"Open Angle Glaucoma","Ocular Hypertension",[787,808,809],"Ofloxacin","Prednisolone",{"nctId":811,"briefTitle":812,"status":304,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT03933631","Pilocarpine Use After Kahook Goniotomy",[89],"2028-06","2028-12","2019-05-01",142,[819],"Glaucoma",[787,809,808],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"intervention":808,"totalTrials":398,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":843,"NA":845},{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":219,"soonestReadout":814},[835,839],{"nctId":798,"briefTitle":799,"status":800,"phases":836,"primaryCompletion":802,"completion":802,"start":803,"enrollment":99,"conditions":837,"interventions":838},[89],[805,806],[787,808,809],{"nctId":811,"briefTitle":812,"status":304,"phases":840,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":841,"interventions":842},[89],[819],[787,809,808],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"intervention":809,"totalTrials":398,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":865,"NA":867},{"trials":850,"activeCount":99},[],{"trials":852,"activeCount":99},[],{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":219,"soonestReadout":814},[857,861],{"nctId":798,"briefTitle":799,"status":800,"phases":858,"primaryCompletion":802,"completion":802,"start":803,"enrollment":99,"conditions":859,"interventions":860},[89],[805,806],[787,808,809],{"nctId":811,"briefTitle":812,"status":304,"phases":862,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":863,"interventions":864},[89],[819],[787,809,808],{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[],{"intervention":870,"totalTrials":219,"cells":871},"Fosaprepitant 150 mg",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":889,"NA":891},{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":219,"soonestReadout":751},[880],{"nctId":881,"briefTitle":882,"status":304,"phases":883,"primaryCompletion":751,"completion":751,"start":884,"enrollment":885,"conditions":886,"interventions":887},"NCT06382012","Antiemetic Fosaprepitant To Remedy Nausea and Vomiting",[88,89],"2024-11-13",200,[214,215,216],[870,888],"Ondansetron 4 mg",{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"intervention":888,"totalTrials":219,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":907,"NA":909},{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"trials":900,"activeCount":99},[],{"trials":902,"activeCount":219,"soonestReadout":751},[903],{"nctId":881,"briefTitle":882,"status":304,"phases":904,"primaryCompletion":751,"completion":751,"start":884,"enrollment":885,"conditions":905,"interventions":906},[88,89],[214,215,216],[870,888],{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[],{"intervention":777,"totalTrials":219,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":219,"soonestReadout":774},[921],{"nctId":771,"briefTitle":772,"status":208,"phases":922,"primaryCompletion":774,"completion":774,"start":211,"enrollment":753,"conditions":923,"interventions":924},[89],[658],[269,777],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"intervention":41,"totalTrials":930,"cells":931},3,{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":961,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":398,"soonestReadout":940},[936,950],{"nctId":937,"briefTitle":938,"status":304,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":947},"NCT07283094","FHD-286 With Low-Dose Weekly Decitabine\u002FVenetoclax in Patients With Acute Myeloid Leukemia",[87],"2028-05","2030-02","2026-02-03",33,[945,946],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[948,41,949],"Decitabine","FHD-286",{"nctId":951,"briefTitle":952,"status":304,"phases":953,"primaryCompletion":815,"completion":815,"start":954,"enrollment":202,"conditions":955,"interventions":957},"NCT05342584","Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS",[87],"2022-05-25",[945,956],"Myelodysplastic Syndromes",[958,959,960],"Venetoclax Oral","Daunorubicin","Cytarabine",{"trials":962,"activeCount":219,"soonestReadout":40},[963],{"nctId":38,"briefTitle":39,"status":304,"phases":964,"primaryCompletion":40,"completion":751,"start":965,"enrollment":966,"conditions":967,"interventions":969},[88],"2022-03-23",91,[956,945,968],"Chronic Myelomonocytic Leukemia",[41,948],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":99},[],{"trials":975,"activeCount":99},[],{"intervention":948,"totalTrials":398,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":986,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":219,"soonestReadout":940},[982],{"nctId":937,"briefTitle":938,"status":304,"phases":983,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":984,"interventions":985},[87],[945,946],[948,41,949],{"trials":987,"activeCount":219,"soonestReadout":40},[988],{"nctId":38,"briefTitle":39,"status":304,"phases":989,"primaryCompletion":40,"completion":751,"start":965,"enrollment":966,"conditions":990,"interventions":991},[88],[956,945,968],[41,948],{"trials":993,"activeCount":99},[],{"trials":995,"activeCount":99},[],{"trials":997,"activeCount":99},[],{"intervention":46,"totalTrials":219,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":219,"soonestReadout":45},[1006],{"nctId":43,"briefTitle":44,"status":1007,"phases":1008,"primaryCompletion":45,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"ACTIVE_NOT_RECRUITING",[88],"2030-05","2023-01-25",17,[1013],"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",[46,1015],"Platinum Doublet",{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"intervention":1015,"totalTrials":219,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":219,"soonestReadout":45},[1030],{"nctId":43,"briefTitle":44,"status":1007,"phases":1031,"primaryCompletion":45,"completion":1009,"start":1010,"enrollment":1011,"conditions":1032,"interventions":1033},[88],[1013],[46,1015],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"intervention":1041,"totalTrials":219,"cells":1042},"Desloratodine",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":99},[],{"trials":1048,"activeCount":219,"soonestReadout":1053},[1049],{"nctId":1050,"briefTitle":1051,"status":304,"phases":1052,"primaryCompletion":1053,"completion":1054,"start":50,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT07109817","Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer",[88],"2029-09","2030-09",116,[29,1057],"Peripheral Neuropathy",[1041],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[],{"intervention":1066,"totalTrials":219,"cells":1067},"Durvalumab",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":219,"soonestReadout":774},[1074],{"nctId":1075,"briefTitle":1076,"status":208,"phases":1077,"primaryCompletion":774,"completion":1078,"start":211,"enrollment":1079,"conditions":1080,"interventions":1082},"NCT07146230","The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2",[88],"2028-10",52,[1081],"Non-small Cell Lung Cancer",[1066,1083,1084],"Monalizumab","Oleclumab",{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"intervention":1083,"totalTrials":219,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":219,"soonestReadout":774},[1099],{"nctId":1075,"briefTitle":1076,"status":208,"phases":1100,"primaryCompletion":774,"completion":1078,"start":211,"enrollment":1079,"conditions":1101,"interventions":1102},[88],[1081],[1066,1083,1084],{"trials":1104,"activeCount":99},[],{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"intervention":1084,"totalTrials":219,"cells":1110},{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":219,"soonestReadout":774},[1117],{"nctId":1075,"briefTitle":1076,"status":208,"phases":1118,"primaryCompletion":774,"completion":1078,"start":211,"enrollment":1079,"conditions":1119,"interventions":1120},[88],[1081],[1066,1083,1084],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"intervention":51,"totalTrials":219,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":219,"soonestReadout":50},[1135],{"nctId":48,"briefTitle":49,"status":304,"phases":1136,"primaryCompletion":50,"completion":50,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},[87,88],"2020-12-01",35,[1140],"Mitral Regurgitation",[51],{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"intervention":1149,"totalTrials":219,"cells":1150},"Cemiplimab",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1152,"activeCount":99},[],{"trials":1154,"activeCount":99},[],{"trials":1156,"activeCount":219,"soonestReadout":1161},[1157],{"nctId":1158,"briefTitle":1159,"status":304,"phases":1160,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":8,"conditions":1163,"interventions":1166},"NCT06865339","Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer",[88],"2027-08","2025-08-07",[1164,1165],"NSCLC","Locally Advanced",[1149,1167,1168],"Fianlimab","Platinum Doublet Chemotherapy",{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[],{"intervention":1167,"totalTrials":219,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":219,"soonestReadout":1161},[1183],{"nctId":1158,"briefTitle":1159,"status":304,"phases":1184,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":8,"conditions":1185,"interventions":1186},[88],[1164,1165],[1149,1167,1168],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[],{"intervention":1168,"totalTrials":219,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":219,"soonestReadout":1161},[1201],{"nctId":1158,"briefTitle":1159,"status":304,"phases":1202,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":8,"conditions":1203,"interventions":1204},[88],[1164,1165],[1149,1167,1168],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[],{"intervention":1212,"totalTrials":219,"cells":1213},"Cannabidivarin",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1215,"activeCount":99},[],{"trials":1217,"activeCount":99},[],{"trials":1219,"activeCount":219,"soonestReadout":210},[1220],{"nctId":1221,"briefTitle":1222,"status":304,"phases":1223,"primaryCompletion":210,"completion":210,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT03202303","Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)",[88],"2019-04-12",100,[1227],"Autism Spectrum Disorder",[1212,1229],"Matched Placebo",{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[],{"intervention":1229,"totalTrials":219,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1239,"activeCount":99},[],{"trials":1241,"activeCount":99},[],{"trials":1243,"activeCount":219,"soonestReadout":210},[1244],{"nctId":1221,"briefTitle":1222,"status":304,"phases":1245,"primaryCompletion":210,"completion":210,"start":1224,"enrollment":1225,"conditions":1246,"interventions":1247},[88],[1227],[1212,1229],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[],{"intervention":1255,"totalTrials":219,"cells":1256},"DFMO",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[],{"trials":1262,"activeCount":219,"soonestReadout":1267},[1263],{"nctId":1264,"briefTitle":1265,"status":304,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1273},"NCT06892678","DFMO Maintenance for Patients With Relapsed\u002FRefractory Ewing Sarcoma or Osteosarcoma",[87,88],"2030-04","2025-04-07",15,[1271,1272],"Osteosarcoma Recurrent","Ewing's Tumor Recurrent",[1255],{"trials":1275,"activeCount":99},[],{"trials":1277,"activeCount":99},[],{"trials":1279,"activeCount":99},[],{"intervention":79,"totalTrials":398,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1294,"PHASE3":1296,"PHASE4":1298,"NA":1312},{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":219,"soonestReadout":78},[1286],{"nctId":76,"briefTitle":77,"status":304,"phases":1287,"primaryCompletion":78,"completion":78,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1292},[87],"2024-10-31",94,[1291],"Cervical Preparation",[79,1293],"Misoprostol",{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[1300],{"nctId":1301,"briefTitle":1302,"status":257,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1311},"NCT02620904","Mifepristone Induction for Fetal Demise",[90],"2019-10","2020-01","2016-07-14",9,[1309,1310],"Intrauterine Fetal Demise","Fetal Death",[79],{"trials":1313,"activeCount":99},[],{"intervention":1315,"totalTrials":219,"cells":1316},"Danvatirsen",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":219,"soonestReadout":1325},[1321],{"nctId":1322,"briefTitle":1323,"status":304,"phases":1324,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT05986240","Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed\u002FRefractory MDS & AML",[87],"2027-06","2030-03","2024-05-08",38,[1330,945,956],"AML\u002FMDS",[1315,1332],"Danvatirsen + Venetoclax",{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[],{"trials":1340,"activeCount":99},[],{"intervention":1332,"totalTrials":219,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":99},[],{"trials":1346,"activeCount":219,"soonestReadout":1325},[1347],{"nctId":1322,"briefTitle":1323,"status":304,"phases":1348,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":1349,"interventions":1350},[87],[1330,945,956],[1315,1332],{"trials":1352,"activeCount":99},[],{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"intervention":949,"totalTrials":219,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":219,"soonestReadout":940},[1365],{"nctId":937,"briefTitle":938,"status":304,"phases":1366,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":1367,"interventions":1368},[87],[945,946],[948,41,949],{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"intervention":959,"totalTrials":219,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1380,"activeCount":99},[],{"trials":1382,"activeCount":219,"soonestReadout":815},[1383],{"nctId":951,"briefTitle":952,"status":304,"phases":1384,"primaryCompletion":815,"completion":815,"start":954,"enrollment":202,"conditions":1385,"interventions":1386},[87],[945,956],[958,959,960],{"trials":1388,"activeCount":99},[],{"trials":1390,"activeCount":99},[],{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"intervention":960,"totalTrials":219,"cells":1396},{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":219,"soonestReadout":815},[1401],{"nctId":951,"briefTitle":952,"status":304,"phases":1402,"primaryCompletion":815,"completion":815,"start":954,"enrollment":202,"conditions":1403,"interventions":1404},[87],[945,956],[958,959,960],{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[],{"trials":1410,"activeCount":99},[],{"trials":1412,"activeCount":99},[],{"intervention":55,"totalTrials":219,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":219,"soonestReadout":50},[1419],{"nctId":53,"briefTitle":54,"status":304,"phases":1420,"primaryCompletion":50,"completion":50,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1428},[87],"2021-06-14",84,[1424,1425,1426,1427],"Subarachnoid Hemorrhage","Intracerebral Hemorrhage","Ventriculitis, Cerebral","Hydrocephalus",[55,1429],"24 hours antibiotics",{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"intervention":1429,"totalTrials":219,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1441,"activeCount":99},[],{"trials":1443,"activeCount":219,"soonestReadout":50},[1444],{"nctId":53,"briefTitle":54,"status":304,"phases":1445,"primaryCompletion":50,"completion":50,"start":1421,"enrollment":1422,"conditions":1446,"interventions":1447},[87],[1424,1425,1426,1427],[55,1429],{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"intervention":1293,"totalTrials":1457,"cells":1458},4,{"EARLY_PHASE1":1459,"PHASE1":1472,"PHASE2":1478,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1460,"activeCount":99},[1461],{"nctId":1462,"briefTitle":1463,"status":800,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":99,"conditions":1467,"interventions":1471},"NCT04768010","Misoprostol for Bloating and Distension",[86],"2023-09-18","2023-08",[1468,1469,1470],"Distension","Gas Bloat Syndrome","Constipation",[1293],{"trials":1473,"activeCount":219,"soonestReadout":78},[1474],{"nctId":76,"briefTitle":77,"status":304,"phases":1475,"primaryCompletion":78,"completion":78,"start":1288,"enrollment":1289,"conditions":1476,"interventions":1477},[87],[1291],[79,1293],{"trials":1479,"activeCount":99},[1480],{"nctId":1481,"briefTitle":1482,"status":107,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":331,"enrollment":1486,"conditions":1487,"interventions":1489},"NCT02680314","Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?",[88],"2017-05-17","2021-06-16",243,[1488],"Labor; Forced or Induced, Affecting Fetus or Newborn",[1293],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[1496],{"nctId":1497,"briefTitle":1498,"status":107,"phases":1499,"primaryCompletion":1500,"completion":1500,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1508},"NCT02314728","Cervical Ripening in Premature Rupture of Membranes",[91],"2016-05-30","2014-10-01",230,[1504,1505,1506,1507],"Pregnancy","Premature Rupture of Membranes","Preterm Premature Rupture of Membranes","Unfavorable Cervix",[1293,1509],"Oxytocin",{"intervention":1511,"totalTrials":398,"cells":1512},"Sildenafil",{"EARLY_PHASE1":1513,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1514,"activeCount":219,"soonestReadout":1519},[1515,1524],{"nctId":1516,"briefTitle":1517,"status":304,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":379,"conditions":1521,"interventions":1523},"NCT06510322","Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support",[86],"2029-12","2025-03-12",[1522],"Vascular Diseases",[1511],{"nctId":1525,"briefTitle":1526,"status":107,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1534},"NCT03199612","Sildenafil To Prevent Clot",[86],"2023-01-20","2019-06-03",20,[1532,1533],"Thrombosis","Hemolysis",[1511],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"intervention":1546,"totalTrials":219,"cells":1547},"Varenicline",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"trials":1557,"activeCount":99},[],{"trials":1559,"activeCount":219,"soonestReadout":751},[1560],{"nctId":1561,"briefTitle":1562,"status":304,"phases":1563,"primaryCompletion":751,"completion":751,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1569},"NCT05642715","Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes",[91],"2024-04-04",400,[1567,1568],"Hiv","Tobacco Use",[1546],{"intervention":59,"totalTrials":219,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":219,"soonestReadout":50},[1584],{"nctId":57,"briefTitle":58,"status":304,"phases":1585,"primaryCompletion":50,"completion":50,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1590},[],"2022-02-15",60,[1589],"Chronic Rhinosinusitis With Nasal Polyps",[59],{"intervention":449,"totalTrials":22,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1608,"PHASE4":1637,"NA":1695},{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[1599],{"nctId":1600,"briefTitle":1601,"status":107,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":416,"conditions":1605,"interventions":1606},"NCT00195910","Safety and Efficacy Study of Hydromorphone and Morphine",[88],"2005-01","2004-10",[18],[1607,449],"Morphine",{"trials":1609,"activeCount":99},[1610,1620,1627],{"nctId":1611,"briefTitle":1612,"status":107,"phases":1613,"primaryCompletion":1614,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1618},"NCT00627367","Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain",[89],"2008-03","2007-12",224,[21],[449,1619],"Nonprotocolized",{"nctId":1621,"briefTitle":1622,"status":107,"phases":1623,"primaryCompletion":170,"completion":170,"start":237,"enrollment":1624,"conditions":1625,"interventions":1626},"NCT00305058","Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain",[88,89],194,[21],[1607,449],{"nctId":1628,"briefTitle":1629,"status":107,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1635},"NCT00825370","Protocolized vs Discretionary Use of Opioids in Acute Pain",[89],"2009-05","2008-10",350,[18],[449,1636],"IV opioid",{"trials":1638,"activeCount":99},[1639,1649,1653,1660,1668,1678,1685],{"nctId":1640,"briefTitle":1641,"status":107,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":161,"conditions":1645,"interventions":1647},"NCT03107481","Acetaminophen IV vs Hydromorphone IV in the ED",[90],"2017-11-14","2017-06-04",[1646],"Pain, Acute",[1648,449],"Acetaminophen",{"nctId":439,"briefTitle":440,"status":107,"phases":1650,"primaryCompletion":442,"completion":443,"start":444,"enrollment":445,"conditions":1651,"interventions":1652},[90],[447],[449,69],{"nctId":1654,"briefTitle":1655,"status":107,"phases":1656,"primaryCompletion":147,"completion":147,"start":123,"enrollment":1633,"conditions":1657,"interventions":1658},"NCT01429298","Comparing Intravenous Hydromorphone to Usual Care",[90],[18],[449,1659],"Usual care",{"nctId":1661,"briefTitle":1662,"status":107,"phases":1663,"primaryCompletion":1664,"completion":1664,"start":1665,"enrollment":1502,"conditions":1666,"interventions":1667},"NCT00682435","Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients",[90],"2007-11","2007-08",[18],[449],{"nctId":1669,"briefTitle":1670,"status":107,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1674,"conditions":1675,"interventions":1677},"NCT01892709","Titration of Intravenous Hydromorphone",[90],"2014-04","2013-06",215,[1676],"Acute Severe Pain",[449],{"nctId":1679,"briefTitle":1680,"status":107,"phases":1681,"primaryCompletion":1682,"completion":1682,"start":355,"enrollment":1633,"conditions":1683,"interventions":1684},"NCT01429285","Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain",[90],"2012-06",[18],[449,1659],{"nctId":1686,"briefTitle":1687,"status":107,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1694},"NCT02389829","Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine",[90],"2016-06","2016-10","2015-03",127,[24],[449,174,116],{"trials":1696,"activeCount":99},[],{"intervention":1648,"totalTrials":30,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1717,"PHASE4":1747,"NA":1763},{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[1705],{"nctId":1706,"briefTitle":1707,"status":107,"phases":1708,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":368,"conditions":1712,"interventions":1714},"NCT03588910","Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription",[88],"2019-07-04","2019-08-04","2018-08-08",[1713],"Surgery",[1648,1715,1716],"Ibuprofen 600 mg","Oxycodone",{"trials":1718,"activeCount":99},[1719,1727,1738],{"nctId":1720,"briefTitle":1721,"status":107,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":368,"conditions":1725,"interventions":1726},"NCT03554018","Ibuprofen With or Without Acetaminophen for Low Back Pain",[89],"2019-09-30","2018-10-16",[26],[1648,1715],{"nctId":1728,"briefTitle":1729,"status":107,"phases":1730,"primaryCompletion":965,"completion":965,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT03584373","Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.",[89],"2018-07-27",119,[1734],"Nephrolithiasis",[1736,1648,1737],"Ketorolac Oral Tablet [Toradol]","Oxycodone Acetaminophen",{"nctId":1739,"briefTitle":1740,"status":800,"phases":1741,"primaryCompletion":1742,"completion":1742,"start":1743,"enrollment":99,"conditions":1744,"interventions":1746},"NCT04360135","Preemptive Acetaminophen for Postoperative Pain Control Following Minimally Invasive Hysterectomy",[88,89],"2021-03-08","2020-05-06",[1745],"Post Operative Pain",[1648],{"trials":1748,"activeCount":99},[1749,1753],{"nctId":1640,"briefTitle":1641,"status":107,"phases":1750,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":161,"conditions":1751,"interventions":1752},[90],[1646],[1648,449],{"nctId":1754,"briefTitle":1755,"status":107,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT04122443","Acetaminophen (APAP) +\u002F- Oxycodone",[90],"2022-07-31","2019-12-01",393,[1761],"Musculoskeletal Pain",[1648,1716],{"trials":1764,"activeCount":99},[],{"intervention":1766,"totalTrials":35,"cells":1767},"Bupivacaine",{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1781,"PHASE3":1805,"PHASE4":1816,"NA":1827},{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[1772],{"nctId":1773,"briefTitle":1774,"status":107,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":161,"conditions":1778,"interventions":1780},"NCT05707754","Sphenopalatine Ganglion Block Study",[87],"2024-08-30","2023-03-06",[1779],"Sphenopalatine Ganglion Nerve Block",[1766],{"trials":1782,"activeCount":99},[1783,1796],{"nctId":1784,"briefTitle":1785,"status":257,"phases":1786,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1793},"NCT03383588","Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section",[88],"2018-08-17","2018-12-31","2018-07-19",26,[1792],"Pain, Referred",[1766,1607,1794,1795],"Fentanyl","Epinephrine",{"nctId":1797,"briefTitle":1798,"status":800,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":99,"conditions":1802,"interventions":1804},"NCT04477525","The Feasibility of Performing Erector Spinae (ESP) Nerve Block in Bariatric Patients; a Case Series Study",[88],"2022-06","2021-06-22",[1803],"Nerve Pain",[1766],{"trials":1806,"activeCount":99},[1807],{"nctId":1808,"briefTitle":1809,"status":107,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1815},"NCT02665273","Greater Occipital Nerve Block With Bupivacaine for Acute Migraine",[89],"2018-01","2015-07-01",28,[24],[1766],{"trials":1817,"activeCount":99},[1818],{"nctId":1819,"briefTitle":1820,"status":257,"phases":1821,"primaryCompletion":1822,"completion":1822,"start":1823,"enrollment":930,"conditions":1824,"interventions":1826},"NCT05972681","The PAIN (Pelvic Area Injection for Numbness) Study",[90],"2025-10-19","2025-04-08",[1825],"Vaginal Laceration During Delivery",[1766,1795],{"trials":1828,"activeCount":99},[],{"intervention":152,"totalTrials":1457,"cells":1830},{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1848,"PHASE4":1850,"NA":1871},{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[1837],{"nctId":1838,"briefTitle":1839,"status":107,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":1843,"conditions":1844,"interventions":1846},"NCT02956616","Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay",[88],"2018-06-15","2017-09-01",118,[1845],"Cesarean Section",[1847],"ketorolac",{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[1852,1856,1867],{"nctId":143,"briefTitle":144,"status":107,"phases":1853,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":1854,"interventions":1855},[90],[150],[94,152,153],{"nctId":1857,"briefTitle":1858,"status":107,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":416,"conditions":1862,"interventions":1864},"NCT03861611","A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain.",[90],"2021-02-02","2019-07-12",[1863,26],"Back Pain Without Radiation",[152,1865,1866],"Ibuprofen","Diclofenac",{"nctId":186,"briefTitle":187,"status":107,"phases":1868,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":1869,"interventions":1870},[90],[194],[94,152],{"trials":1872,"activeCount":99},[],{"intervention":116,"totalTrials":1457,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1885,"PHASE4":1891,"NA":1901},{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[1881],{"nctId":105,"briefTitle":106,"status":107,"phases":1882,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":1883,"interventions":1884},[87,88],[114],[94,116],{"trials":1886,"activeCount":99},[1887],{"nctId":131,"briefTitle":132,"status":107,"phases":1888,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":1889,"interventions":1890},[89],[114],[94,116,139],{"trials":1892,"activeCount":99},[1893,1897],{"nctId":176,"briefTitle":177,"status":107,"phases":1894,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":1895,"interventions":1896},[90],[24],[128,184],{"nctId":1686,"briefTitle":1687,"status":107,"phases":1898,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1899,"interventions":1900},[90],[24],[449,174,116],{"trials":1902,"activeCount":99},[],{"intervention":1904,"totalTrials":930,"cells":1905},"Normal Saline",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1922,"PHASE4":1928,"NA":1941},{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[1912],{"nctId":1913,"briefTitle":1914,"status":107,"phases":1915,"primaryCompletion":1614,"completion":1916,"start":170,"enrollment":1917,"conditions":1918,"interventions":1920},"NCT00811187","Paracervical Block During Office Hysteroscopy",[88],"2008-09",80,[1919],"Paracervical Block",[1921,1904],"Lidocaine paracervical block",{"trials":1923,"activeCount":99},[1924],{"nctId":131,"briefTitle":132,"status":107,"phases":1925,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":1926,"interventions":1927},[89],[114],[94,116,139],{"trials":1929,"activeCount":99},[1930],{"nctId":1931,"briefTitle":1932,"status":107,"phases":1933,"primaryCompletion":1934,"start":1935,"enrollment":1936,"conditions":1937,"interventions":1939},"NCT01482091","Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis",[90],"2015-02","2011-12",124,[1938,18],"Anemia, Sickle Cell",[1940,1904],"Fentanyl Citrate",{"trials":1942,"activeCount":99},[],{"intervention":1716,"totalTrials":930,"cells":1944},{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1955,"PHASE4":1968,"NA":1974},{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[1951],{"nctId":1706,"briefTitle":1707,"status":107,"phases":1952,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":368,"conditions":1953,"interventions":1954},[88],[1713],[1648,1715,1716],{"trials":1956,"activeCount":99},[1957],{"nctId":1958,"briefTitle":1959,"status":107,"phases":1960,"primaryCompletion":1961,"completion":1961,"start":377,"enrollment":1962,"conditions":1963,"interventions":1965},"NCT01402375","Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge",[89],"2014-11",720,[1964],"Analgesia After ED Discharge for Extremity Injuries",[1966,1967,1716,1967,1716,1966],"Hydrocodone","Codeine",{"trials":1969,"activeCount":99},[1970],{"nctId":1754,"briefTitle":1755,"status":107,"phases":1971,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":1759,"conditions":1972,"interventions":1973},[90],[1761],[1648,1716],{"trials":1975,"activeCount":99},[],{"intervention":1715,"totalTrials":930,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1988,"PHASE4":1994,"NA":2009},{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[1984],{"nctId":1706,"briefTitle":1707,"status":107,"phases":1985,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":368,"conditions":1986,"interventions":1987},[88],[1713],[1648,1715,1716],{"trials":1989,"activeCount":99},[1990],{"nctId":1720,"briefTitle":1721,"status":107,"phases":1991,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":368,"conditions":1992,"interventions":1993},[89],[26],[1648,1715],{"trials":1995,"activeCount":99},[1996],{"nctId":1997,"briefTitle":1998,"status":107,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":2003,"conditions":2004,"interventions":2005},"NCT03068897","Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain",[90],"2018-07-11","2018-10-11","2017-05-03",320,[26],[2006,2007,2008,1715],"Metaxalone","Tizanidine","Baclofen",{"trials":2010,"activeCount":99},[],{"intervention":1795,"totalTrials":398,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2031},{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[2019],{"nctId":1784,"briefTitle":1785,"status":257,"phases":2020,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":2021,"interventions":2022},[88],[1792],[1766,1607,1794,1795],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[2027],{"nctId":1819,"briefTitle":1820,"status":257,"phases":2028,"primaryCompletion":1822,"completion":1822,"start":1823,"enrollment":930,"conditions":2029,"interventions":2030},[90],[1825],[1766,1795],{"trials":2032,"activeCount":99},[],{"intervention":2034,"totalTrials":398,"cells":2035},"Fresh Frozen Plasma",{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2053,"PHASE4":2055,"NA":2064},{"trials":2037,"activeCount":99},[],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[2042],{"nctId":2043,"briefTitle":2044,"status":800,"phases":2045,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":99,"conditions":2048,"interventions":2051},"NCT04109144","Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis",[88],"2023-07","2019-11-11",[2049,2050],"Liver Cirrhosis","Ascites Hepatic",[2034,2052],"Albumin",{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[2057],{"nctId":2058,"briefTitle":2044,"status":800,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":99,"conditions":2062,"interventions":2063},"NCT03202524",[90],"2018-07","2017-12",[2049,2050],[2034,2052],{"trials":2065,"activeCount":99},[],{"intervention":2052,"totalTrials":398,"cells":2067},{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2078,"PHASE4":2080,"NA":2086},{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[2074],{"nctId":2043,"briefTitle":2044,"status":800,"phases":2075,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":99,"conditions":2076,"interventions":2077},[88],[2049,2050],[2034,2052],{"trials":2079,"activeCount":99},[],{"trials":2081,"activeCount":99},[2082],{"nctId":2058,"briefTitle":2044,"status":800,"phases":2083,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":99,"conditions":2084,"interventions":2085},[90],[2049,2050],[2034,2052],{"trials":2087,"activeCount":99},[],{"intervention":2089,"totalTrials":398,"cells":2090},"Mycophenolate mofetil",{"EARLY_PHASE1":2091,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2135},{"trials":2092,"activeCount":99},[2093],{"nctId":2094,"briefTitle":2095,"status":257,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":2099,"interventions":2103},"NCT02653196","A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors",[86],"2017-08","2015-09",[2100,2101,2102],"Neuroepithelial Tumor","Solid Tumor","Allogeneic Hematopoietic Stem Cell Transplantation",[2104,2105,2106,2107,2108,2109,2110,2111,2089],"Keratinocyte Growth Factor","Alemtuzumab","Thiotepa","Etoposide","Fludarabine","Melphalan","Tacrolimus","Cyclosporine A",{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[2120],{"nctId":2121,"briefTitle":2122,"status":800,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":99,"conditions":2127,"interventions":2130},"NCT03315052","Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects",[90],"2021-01","2022-01","2019-01",[2128,2129],"Acute Cellular Graft Rejection","Liver Transplant Rejection",[2131,2132,2133,2134],"Budesonide","Tacrolimus（FK506）","Mycophenolate Mofetil","Prednisone",{"trials":2136,"activeCount":99},[],{"intervention":1659,"totalTrials":398,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2157},{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[2149,2153],{"nctId":1654,"briefTitle":1655,"status":107,"phases":2150,"primaryCompletion":147,"completion":147,"start":123,"enrollment":1633,"conditions":2151,"interventions":2152},[90],[18],[449,1659],{"nctId":1679,"briefTitle":1680,"status":107,"phases":2154,"primaryCompletion":1682,"completion":1682,"start":355,"enrollment":1633,"conditions":2155,"interventions":2156},[90],[18],[449,1659],{"trials":2158,"activeCount":99},[],{"intervention":2134,"totalTrials":398,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2178,"PHASE4":2180,"NA":2186},{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[],{"trials":2166,"activeCount":99},[2167],{"nctId":2168,"briefTitle":2169,"status":107,"phases":2170,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":2173,"conditions":2174,"interventions":2176},"NCT03565835","Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer",[88],"2021-11-17","2018-06-13",31,[2175],"Prostatic Neoplasms",[2177,2134],"Abiraterone Acetate",{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[2182],{"nctId":2121,"briefTitle":2122,"status":800,"phases":2183,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":99,"conditions":2184,"interventions":2185},[90],[2128,2129],[2131,2132,2133,2134],{"trials":2187,"activeCount":99},[],{"intervention":174,"totalTrials":398,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2208},{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[2200,2204],{"nctId":167,"briefTitle":168,"status":107,"phases":2201,"primaryCompletion":170,"completion":170,"start":171,"enrollment":8,"conditions":2202,"interventions":2203},[90],[24],[174,94],{"nctId":1686,"briefTitle":1687,"status":107,"phases":2205,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":2206,"interventions":2207},[90],[24],[449,174,116],{"trials":2209,"activeCount":99},[],{"intervention":2211,"totalTrials":398,"cells":2212},"Insulin",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2228,"PHASE4":2230,"NA":2242},{"trials":2214,"activeCount":99},[],{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[2219],{"nctId":2220,"briefTitle":2221,"status":107,"phases":2222,"primaryCompletion":2223,"completion":2223,"start":170,"enrollment":22,"conditions":2224,"interventions":2226},"NCT00456300","Role of Exenatide in Type 1 Diabetes",[88],"2009-03",[2225],"Type 1 Diabetes",[2227,2211],"Exenatide",{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[2232],{"nctId":2233,"briefTitle":2234,"status":107,"phases":2235,"primaryCompletion":2236,"completion":2236,"start":2237,"enrollment":27,"conditions":2238,"interventions":2240},"NCT00442767","Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus",[90],"2009-02","2007-02",[2239],"Type 1 Diabetes Mellitus",[2211,2241],"Pramlintide + Insulin",{"trials":2243,"activeCount":99},[],{"intervention":300,"totalTrials":398,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2260,"PHASE4":2262,"NA":2268},{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":99},[2252],{"nctId":2253,"briefTitle":2254,"status":800,"phases":2255,"primaryCompletion":333,"completion":333,"start":2256,"enrollment":99,"conditions":2257,"interventions":2259},"NCT03613558","Dex as Analgesic Adjuvant in OSA Patients",[87,88],"2014-07",[2258],"Obstructive Sleep Apnea",[300],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[2264],{"nctId":289,"briefTitle":290,"status":107,"phases":2265,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":2266,"interventions":2267},[90],[297],[299,300,164],{"trials":2269,"activeCount":99},[],{"intervention":2271,"totalTrials":219,"cells":2272},"CT-guided corticosteroid+ bupivicaine",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2294},{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[2283],{"nctId":2284,"briefTitle":2285,"status":257,"phases":2286,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":219,"conditions":2289,"interventions":2292},"NCT01267825","CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial",[90],"2013-08","2010-09-01",[2290,2291],"Disc Herniation","Lumbosacral Radiculopathy",[2271,2293],"Standard medical care",{"trials":2295,"activeCount":99},[],{"intervention":2293,"totalTrials":219,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2306,"NA":2312},{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[2308],{"nctId":2284,"briefTitle":2285,"status":257,"phases":2309,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":219,"conditions":2310,"interventions":2311},[90],[2290,2291],[2271,2293],{"trials":2313,"activeCount":99},[],{"intervention":419,"totalTrials":219,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2322,"PHASE4":2324,"NA":2330},{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[],{"trials":2321,"activeCount":99},[],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[2326],{"nctId":411,"briefTitle":412,"status":107,"phases":2327,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":2328,"interventions":2329},[90],[26],[313,419],{"trials":2331,"activeCount":99},[],{"intervention":2333,"totalTrials":219,"cells":2334},"topiramate",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2354},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[],{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[2345],{"nctId":2346,"briefTitle":2347,"status":107,"phases":2348,"completion":171,"start":2349,"enrollment":2350,"conditions":2351,"interventions":2353},"NCT00211744","Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder",[90],"2004-08",24,[2352],"Obsessive-compulsive Disorder",[2333],{"trials":2355,"activeCount":99},[],{"intervention":1940,"totalTrials":219,"cells":2357},{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2364,"PHASE4":2366,"NA":2372},{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"trials":2365,"activeCount":99},[],{"trials":2367,"activeCount":99},[2368],{"nctId":1931,"briefTitle":1932,"status":107,"phases":2369,"primaryCompletion":1934,"start":1935,"enrollment":1936,"conditions":2370,"interventions":2371},[90],[1938,18],[1940,1904],{"trials":2373,"activeCount":99},[],{"intervention":253,"totalTrials":219,"cells":2375},{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2382,"PHASE4":2384,"NA":2390},{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[2386],{"nctId":244,"briefTitle":245,"status":107,"phases":2387,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":2388,"interventions":2389},[90],[114],[164,253],{"trials":2391,"activeCount":99},[],{"intervention":270,"totalTrials":219,"cells":2393},{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2402,"NA":2408},{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[],{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[2404],{"nctId":255,"briefTitle":256,"status":257,"phases":2405,"primaryCompletion":259,"completion":259,"start":260,"enrollment":219,"conditions":2406,"interventions":2407},[90],[262,263,264,265,266,267],[164,269,270],{"trials":2409,"activeCount":99},[],{"intervention":349,"totalTrials":219,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2426},{"trials":2413,"activeCount":99},[],{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[2422],{"nctId":341,"briefTitle":342,"status":107,"phases":2423,"primaryCompletion":344,"completion":345,"start":294,"enrollment":346,"conditions":2424,"interventions":2425},[90],[26],[349,350,317],{"trials":2427,"activeCount":99},[],{"intervention":350,"totalTrials":219,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2436,"PHASE4":2438,"NA":2444},{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[2440],{"nctId":341,"briefTitle":342,"status":107,"phases":2441,"primaryCompletion":344,"completion":345,"start":294,"enrollment":346,"conditions":2442,"interventions":2443},[90],[26],[349,350,317],{"trials":2445,"activeCount":99},[],{"intervention":2447,"totalTrials":219,"cells":2448},"BUP microdose induction",{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2473},{"trials":2450,"activeCount":99},[],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[],{"trials":2458,"activeCount":99},[2459],{"nctId":2460,"briefTitle":2461,"status":257,"phases":2462,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":2466,"conditions":2467,"interventions":2471},"NCT05118204","Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization",[90],"2024-10-23","2025-04-09","2022-09-29",23,[2468,2469,2470],"Substance Use Disorders","Opioid-use Disorder","Chronic Pain",[2447,2472],"TAU",{"trials":2474,"activeCount":99},[],{"intervention":2472,"totalTrials":219,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2483,"PHASE4":2485,"NA":2491},{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":99},[2487],{"nctId":2460,"briefTitle":2461,"status":257,"phases":2488,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":2466,"conditions":2489,"interventions":2490},[90],[2468,2469,2470],[2447,2472],{"trials":2492,"activeCount":99},[],{"intervention":153,"totalTrials":219,"cells":2494},{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2509},{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[2505],{"nctId":143,"briefTitle":144,"status":107,"phases":2506,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":2507,"interventions":2508},[90],[150],[94,152,153],{"trials":2510,"activeCount":99},[],{"intervention":2512,"totalTrials":219,"cells":2513},"Phenazopyridine",{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2518,"PHASE3":2520,"PHASE4":2522,"NA":2536},{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[2524],{"nctId":2525,"briefTitle":2526,"status":800,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":99,"conditions":2530,"interventions":2534},"NCT06514430","Prophylactic Analgesia for Bladder Botox Injections",[90],"2026-02","2025-07",[2531,2532,2533],"Urinary Incontinence","Urinary Incontinence, Urge","Overactive Bladder",[2512,2535],"1% lidocaine with sodium bicarbonate",{"trials":2537,"activeCount":99},[],{"intervention":2535,"totalTrials":219,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2554},{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[2550],{"nctId":2525,"briefTitle":2526,"status":800,"phases":2551,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":99,"conditions":2552,"interventions":2553},[90],[2531,2532,2533],[2512,2535],{"trials":2555,"activeCount":99},[],{"intervention":2557,"totalTrials":219,"cells":2558},"diphenhydramine\u002Fphenylephrine\u002Fcocoa; dextromethorophan; placebo",{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2582},{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[2569],{"nctId":2570,"briefTitle":2571,"status":107,"phases":2572,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2578},"NCT02062710","Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo",[90],"2014-06","2014-01",22,[2577],"Cough Reflex Sensitivity",[2557,2579,2580,2581],"diphenhydramine\u002Fphenylephrine\u002Fcocoa; placebo; dextromethorphan","dextromethorphan; diphenhydramine\u002Fphenylephrine\u002Fcocoa; placebo","dextromethorophan; placebo; diphenhydramine\u002Fphenylephrine\u002Fcocoa",{"trials":2583,"activeCount":99},[],{"intervention":2579,"totalTrials":219,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2600},{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[2596],{"nctId":2570,"briefTitle":2571,"status":107,"phases":2597,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2598,"interventions":2599},[90],[2577],[2557,2579,2580,2581],{"trials":2601,"activeCount":99},[],{"intervention":2580,"totalTrials":219,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2618},{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[2614],{"nctId":2570,"briefTitle":2571,"status":107,"phases":2615,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2616,"interventions":2617},[90],[2577],[2557,2579,2580,2581],{"trials":2619,"activeCount":99},[],{"intervention":2581,"totalTrials":219,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2630,"NA":2636},{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[],{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[2632],{"nctId":2570,"briefTitle":2571,"status":107,"phases":2633,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2634,"interventions":2635},[90],[2577],[2557,2579,2580,2581],{"trials":2637,"activeCount":99},[],{"intervention":1865,"totalTrials":219,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2654},{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[],{"trials":2647,"activeCount":99},[],{"trials":2649,"activeCount":99},[2650],{"nctId":1857,"briefTitle":1858,"status":107,"phases":2651,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":416,"conditions":2652,"interventions":2653},[90],[1863,26],[152,1865,1866],{"trials":2655,"activeCount":99},[],{"intervention":1866,"totalTrials":219,"cells":2657},{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2672},{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":99},[],{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[2668],{"nctId":1857,"briefTitle":1858,"status":107,"phases":2669,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":416,"conditions":2670,"interventions":2671},[90],[1863,26],[152,1865,1866],{"trials":2673,"activeCount":99},[],{"intervention":361,"totalTrials":219,"cells":2675},{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2690},{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"trials":2685,"activeCount":99},[2686],{"nctId":352,"briefTitle":353,"status":107,"phases":2687,"primaryCompletion":355,"completion":355,"start":170,"enrollment":356,"conditions":2688,"interventions":2689},[90],[24,358,359],[361,317],{"trials":2691,"activeCount":99},[],{"intervention":2693,"totalTrials":219,"cells":2694},"Milnacipran",{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2699,"PHASE3":2701,"PHASE4":2703,"NA":2714},{"trials":2696,"activeCount":99},[],{"trials":2698,"activeCount":99},[],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[2705],{"nctId":2706,"briefTitle":2707,"status":107,"phases":2708,"primaryCompletion":2256,"completion":2256,"start":2709,"enrollment":95,"conditions":2710,"interventions":2713},"NCT01337700","Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism",[90],"2011-02",[1227,2711,2712],"Asperger Syndrome","Aspergers Syndrome",[2693],{"trials":2715,"activeCount":99},[],{"intervention":2717,"totalTrials":219,"cells":2718},"Intranasal Ketoralac",{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2725,"PHASE4":2727,"NA":2738},{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[2729],{"nctId":2730,"briefTitle":2731,"status":257,"phases":2732,"primaryCompletion":2573,"completion":2573,"start":2733,"enrollment":379,"conditions":2734,"interventions":2737},"NCT01736358","The Use of Intranasal Ketoralac for Pain Management (Sprix)",[90],"2012-10",[2735,2736],"Postoperative Pain Management","Urolithiasis",[2717],{"trials":2739,"activeCount":99},[],{"intervention":2741,"totalTrials":219,"cells":2742},"IV acetaminophen + 0.5 mg IV hydromorphone",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2762},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[],{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[2753],{"nctId":2754,"briefTitle":2755,"status":107,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":294,"enrollment":2758,"conditions":2759,"interventions":2760},"NCT02621619","IV Acetaminophen as an Analgesic Adjunct",[90],"2017-10",159,[21],[2741,2761],"Normal saline + 0.5 mg IV hydromorphone",{"trials":2763,"activeCount":99},[],{"intervention":2761,"totalTrials":219,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2772,"PHASE4":2774,"NA":2780},{"trials":2767,"activeCount":99},[],{"trials":2769,"activeCount":99},[],{"trials":2771,"activeCount":99},[],{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[2776],{"nctId":2754,"briefTitle":2755,"status":107,"phases":2777,"primaryCompletion":2757,"completion":2757,"start":294,"enrollment":2758,"conditions":2778,"interventions":2779},[90],[21],[2741,2761],{"trials":2781,"activeCount":99},[],{"intervention":165,"totalTrials":219,"cells":2783},{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2798},{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[2794],{"nctId":155,"briefTitle":156,"status":107,"phases":2795,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":2796,"interventions":2797},[90],[24],[128,164,165],{"trials":2799,"activeCount":99},[],{"intervention":2801,"totalTrials":219,"cells":2802},"Dexmedetomidine and Midazolam",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2811,"NA":2825},{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[2813],{"nctId":2814,"briefTitle":2815,"status":107,"phases":2816,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2823},"NCT03255824","A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation",[90],"2019-08-23","2019-12-27","2018-03-20",144,[2822],"Anesthesia",[2801,2824],"Propofol, Midazolam, and Fentanyl",{"trials":2826,"activeCount":99},[],{"intervention":2824,"totalTrials":219,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2843},{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":99},[2839],{"nctId":2814,"briefTitle":2815,"status":107,"phases":2840,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2841,"interventions":2842},[90],[2822],[2801,2824],{"trials":2844,"activeCount":99},[],{"intervention":2846,"totalTrials":219,"cells":2847},"Amoxi Clavulanate",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2854,"PHASE4":2856,"NA":2867},{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[2858],{"nctId":2859,"briefTitle":2860,"status":257,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":2863,"enrollment":2350,"conditions":2864,"interventions":2866},"NCT03369717","Use of Perioperative Antibiotics in Endoscopic Sinus Surgery",[90],"2020-05-07","2018-08-01",[2865],"Chronic Sinus Infection",[2846],{"trials":2868,"activeCount":99},[],{"intervention":382,"totalTrials":219,"cells":2870},{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2877,"PHASE4":2879,"NA":2885},{"trials":2872,"activeCount":99},[],{"trials":2874,"activeCount":99},[],{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[2881],{"nctId":374,"briefTitle":375,"status":107,"phases":2882,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":2883,"interventions":2884},[90],[24],[317,382],{"trials":2886,"activeCount":99},[],{"intervention":2888,"totalTrials":219,"cells":2889},"Sugammadex",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2896,"PHASE4":2898,"NA":2910},{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[],{"trials":2895,"activeCount":99},[],{"trials":2897,"activeCount":99},[],{"trials":2899,"activeCount":99},[2900],{"nctId":2901,"briefTitle":2902,"status":800,"phases":2903,"primaryCompletion":2904,"completion":2904,"start":2905,"enrollment":99,"conditions":2906,"interventions":2908},"NCT03944473","Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries",[90],"2020-07-20","2019-06-20",[2907],"Ambulatory Difficulty",[2888,2909],"Neostigmine",{"trials":2911,"activeCount":99},[],{"intervention":2909,"totalTrials":219,"cells":2913},{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2920,"PHASE4":2922,"NA":2928},{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[2924],{"nctId":2901,"briefTitle":2902,"status":800,"phases":2925,"primaryCompletion":2904,"completion":2904,"start":2905,"enrollment":99,"conditions":2926,"interventions":2927},[90],[2907],[2888,2909],{"trials":2929,"activeCount":99},[],{"intervention":393,"totalTrials":219,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2940,"NA":2946},{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":99},[],{"trials":2937,"activeCount":99},[],{"trials":2939,"activeCount":99},[],{"trials":2941,"activeCount":99},[2942],{"nctId":384,"briefTitle":385,"status":107,"phases":2943,"primaryCompletion":387,"completion":179,"start":388,"enrollment":389,"conditions":2944,"interventions":2945},[90],[391],[317,393,394],{"trials":2947,"activeCount":99},[],{"intervention":394,"totalTrials":219,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2964},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[2960],{"nctId":384,"briefTitle":385,"status":107,"phases":2961,"primaryCompletion":387,"completion":179,"start":388,"enrollment":389,"conditions":2962,"interventions":2963},[90],[391],[317,393,394],{"trials":2965,"activeCount":99},[],{"intervention":2967,"totalTrials":219,"cells":2968},"IV Acetaminophen",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2977,"NA":2988},{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[2979],{"nctId":2980,"briefTitle":2981,"status":107,"phases":2982,"primaryCompletion":179,"completion":179,"start":2983,"enrollment":2984,"conditions":2985,"interventions":2987},"NCT02069184","IV Acetaminophen for Acute Post Operative Pain in C-Section Patients",[90],"2013-11",66,[2986],"Post-operative Pain",[2967],{"trials":2989,"activeCount":99},[],{"intervention":2991,"totalTrials":219,"cells":2992},"Divalproex Sodium ER",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3012},{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[3003],{"nctId":3004,"briefTitle":3005,"status":107,"phases":3006,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":95,"conditions":3009,"interventions":3011},"NCT00211796","Divalproex Sodium ER in Adult Autism",[90],"2007-04","2005-04",[3010],"Autism",[2991],{"trials":3013,"activeCount":99},[],{"intervention":3015,"totalTrials":219,"cells":3016},"TESI",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3025,"NA":3035},{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":99},[],{"trials":3024,"activeCount":99},[],{"trials":3026,"activeCount":99},[3027],{"nctId":3028,"briefTitle":3029,"status":257,"phases":3030,"primaryCompletion":1691,"completion":1691,"start":3031,"enrollment":1457,"conditions":3032,"interventions":3034},"NCT02414698","Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy",[90],"2015-01",[3033],"Lumbar Herniated Disc",[3015],{"trials":3036,"activeCount":99},[],{"intervention":3038,"totalTrials":219,"cells":3039},"metoclopramide 10 mg",{"EARLY_PHASE1":3040,"PHASE1":3042,"PHASE2":3044,"PHASE3":3046,"PHASE4":3048,"NA":3062},{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[3050],{"nctId":3051,"briefTitle":3052,"status":107,"phases":3053,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":3056,"conditions":3057,"interventions":3059},"NCT00475306","The Montefiore Metoclopramide Study",[90],"2008-02","2007-05",289,[215,3058],"Extrapyramidal Symptoms",[3038,3060,3061],"Diphenhydramine 25 mg","Metoclopramide 20 mg",{"trials":3063,"activeCount":99},[],{"intervention":3060,"totalTrials":219,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3080},{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"trials":3071,"activeCount":99},[],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[3076],{"nctId":3051,"briefTitle":3052,"status":107,"phases":3077,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":3056,"conditions":3078,"interventions":3079},[90],[215,3058],[3038,3060,3061],{"trials":3081,"activeCount":99},[],{"intervention":3061,"totalTrials":219,"cells":3083},{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3098},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[],{"trials":3091,"activeCount":99},[],{"trials":3093,"activeCount":99},[3094],{"nctId":3051,"briefTitle":3052,"status":107,"phases":3095,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":3056,"conditions":3096,"interventions":3097},[90],[215,3058],[3038,3060,3061],{"trials":3099,"activeCount":99},[],{"intervention":3101,"totalTrials":219,"cells":3102},"Dexamethasone 4mg",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3107,"PHASE3":3109,"PHASE4":3111,"NA":3123},{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[3113],{"nctId":3114,"briefTitle":3115,"status":107,"phases":3116,"primaryCompletion":3117,"completion":3117,"start":3118,"enrollment":3119,"conditions":3120,"interventions":3121},"NCT04112823","Dexamethasone for Migraine - Dose Comparison",[90],"2022-12-31","2019-12-22",209,[24],[3101,3122],"Dexamethasone 16mg",{"trials":3124,"activeCount":99},[],{"intervention":3122,"totalTrials":219,"cells":3126},{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3133,"PHASE4":3135,"NA":3141},{"trials":3128,"activeCount":99},[],{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[3137],{"nctId":3114,"briefTitle":3115,"status":107,"phases":3138,"primaryCompletion":3117,"completion":3117,"start":3118,"enrollment":3119,"conditions":3139,"interventions":3140},[90],[24],[3101,3122],{"trials":3142,"activeCount":99},[],{"intervention":2131,"totalTrials":219,"cells":3144},{"EARLY_PHASE1":3145,"PHASE1":3147,"PHASE2":3149,"PHASE3":3151,"PHASE4":3153,"NA":3159},{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[3155],{"nctId":2121,"briefTitle":2122,"status":800,"phases":3156,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":99,"conditions":3157,"interventions":3158},[90],[2128,2129],[2131,2132,2133,2134],{"trials":3160,"activeCount":99},[],{"intervention":2132,"totalTrials":219,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3169,"PHASE4":3171,"NA":3177},{"trials":3164,"activeCount":99},[],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[3173],{"nctId":2121,"briefTitle":2122,"status":800,"phases":3174,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":99,"conditions":3175,"interventions":3176},[90],[2128,2129],[2131,2132,2133,2134],{"trials":3178,"activeCount":99},[],{"intervention":284,"totalTrials":219,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3195},{"trials":3182,"activeCount":99},[],{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[3191],{"nctId":276,"briefTitle":277,"status":257,"phases":3192,"primaryCompletion":279,"completion":279,"start":280,"enrollment":95,"conditions":3193,"interventions":3194},[90],[282],[284,164,285,286,287],{"trials":3196,"activeCount":99},[],{"intervention":285,"totalTrials":219,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3207,"NA":3213},{"trials":3200,"activeCount":99},[],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[3209],{"nctId":276,"briefTitle":277,"status":257,"phases":3210,"primaryCompletion":279,"completion":279,"start":280,"enrollment":95,"conditions":3211,"interventions":3212},[90],[282],[284,164,285,286,287],{"trials":3214,"activeCount":99},[],{"intervention":286,"totalTrials":219,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3223,"PHASE4":3225,"NA":3231},{"trials":3218,"activeCount":99},[],{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[3227],{"nctId":276,"briefTitle":277,"status":257,"phases":3228,"primaryCompletion":279,"completion":279,"start":280,"enrollment":95,"conditions":3229,"interventions":3230},[90],[282],[284,164,285,286,287],{"trials":3232,"activeCount":99},[],{"intervention":287,"totalTrials":219,"cells":3234},{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3241,"PHASE4":3243,"NA":3249},{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"trials":3242,"activeCount":99},[],{"trials":3244,"activeCount":99},[3245],{"nctId":276,"briefTitle":277,"status":257,"phases":3246,"primaryCompletion":279,"completion":279,"start":280,"enrollment":95,"conditions":3247,"interventions":3248},[90],[282],[284,164,285,286,287],{"trials":3250,"activeCount":99},[],{"intervention":2006,"totalTrials":219,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3257,"PHASE3":3259,"PHASE4":3261,"NA":3267},{"trials":3254,"activeCount":99},[],{"trials":3256,"activeCount":99},[],{"trials":3258,"activeCount":99},[],{"trials":3260,"activeCount":99},[],{"trials":3262,"activeCount":99},[3263],{"nctId":1997,"briefTitle":1998,"status":107,"phases":3264,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":2003,"conditions":3265,"interventions":3266},[90],[26],[2006,2007,2008,1715],{"trials":3268,"activeCount":99},[],{"intervention":2007,"totalTrials":219,"cells":3270},{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3277,"PHASE4":3279,"NA":3285},{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[3281],{"nctId":1997,"briefTitle":1998,"status":107,"phases":3282,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":2003,"conditions":3283,"interventions":3284},[90],[26],[2006,2007,2008,1715],{"trials":3286,"activeCount":99},[],{"intervention":2008,"totalTrials":219,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3295,"PHASE4":3297,"NA":3303},{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"trials":3294,"activeCount":99},[],{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[3299],{"nctId":1997,"briefTitle":1998,"status":107,"phases":3300,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":2003,"conditions":3301,"interventions":3302},[90],[26],[2006,2007,2008,1715],{"trials":3304,"activeCount":99},[],{"intervention":3306,"totalTrials":219,"cells":3307},"Methadone",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3314,"PHASE4":3316,"NA":3327},{"trials":3309,"activeCount":99},[],{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[3318],{"nctId":3319,"briefTitle":3320,"status":800,"phases":3321,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":99,"conditions":3324,"interventions":3326},"NCT05845359","Intraoperative Methadone for Postoperative Pain Control",[90],"2024-02","2023-09",[3325],"Bariatric Surgery Candidate",[3306],{"trials":3328,"activeCount":99},[],{"intervention":3330,"totalTrials":219,"cells":3331},"Intralesional Triamcinolone 10 mg\u002FmL",{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3338,"PHASE4":3340,"NA":3352},{"trials":3333,"activeCount":99},[],{"trials":3335,"activeCount":99},[],{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[3342],{"nctId":3343,"briefTitle":3344,"status":257,"phases":3345,"primaryCompletion":3346,"completion":3346,"start":3347,"enrollment":22,"conditions":3348,"interventions":3349},"NCT04582669","Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa",[90],"2022-10-12","2022-01-24",[34],[3330,3350,3351],"Intralesional Triamcinolone 20 mg\u002FmL","Intralesional Triamcinolone 40 mg\u002FmL",{"trials":3353,"activeCount":99},[],{"intervention":3350,"totalTrials":219,"cells":3355},{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3362,"PHASE4":3364,"NA":3370},{"trials":3357,"activeCount":99},[],{"trials":3359,"activeCount":99},[],{"trials":3361,"activeCount":99},[],{"trials":3363,"activeCount":99},[],{"trials":3365,"activeCount":99},[3366],{"nctId":3343,"briefTitle":3344,"status":257,"phases":3367,"primaryCompletion":3346,"completion":3346,"start":3347,"enrollment":22,"conditions":3368,"interventions":3369},[90],[34],[3330,3350,3351],{"trials":3371,"activeCount":99},[],{"intervention":3351,"totalTrials":219,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3388},{"trials":3375,"activeCount":99},[],{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"trials":3383,"activeCount":99},[3384],{"nctId":3343,"briefTitle":3344,"status":257,"phases":3385,"primaryCompletion":3346,"completion":3346,"start":3347,"enrollment":22,"conditions":3386,"interventions":3387},[90],[34],[3330,3350,3351],{"trials":3389,"activeCount":99},[],{"intervention":3391,"totalTrials":219,"cells":3392},"Insulin Detemir mixed with RAI",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3413},{"trials":3394,"activeCount":99},[],{"trials":3396,"activeCount":99},[],{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[3403],{"nctId":3404,"briefTitle":3405,"status":107,"phases":3406,"primaryCompletion":3407,"completion":3408,"start":1665,"enrollment":3409,"conditions":3410,"interventions":3411},"NCT00564395","Detemir: Role in Type 1 Diabetes",[90],"2009-12","2010-05",18,[2239],[3391,3412],"Insulin Detemir and RAI",{"trials":3414,"activeCount":99},[],{"intervention":3412,"totalTrials":219,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3423,"PHASE4":3425,"NA":3431},{"trials":3418,"activeCount":99},[],{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[3427],{"nctId":3404,"briefTitle":3405,"status":107,"phases":3428,"primaryCompletion":3407,"completion":3408,"start":1665,"enrollment":3409,"conditions":3429,"interventions":3430},[90],[2239],[3391,3412],{"trials":3432,"activeCount":99},[],{"intervention":3434,"totalTrials":219,"cells":3435},"Sodium nitroprusside",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3442,"PHASE4":3444,"NA":3457},{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":99},[],{"trials":3443,"activeCount":99},[],{"trials":3445,"activeCount":99},[3446],{"nctId":3447,"briefTitle":3448,"status":800,"phases":3449,"primaryCompletion":3450,"completion":3451,"start":3450,"enrollment":99,"conditions":3452,"interventions":3454},"NCT02767024","Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure",[90],"2018-05-01","2018-06-01",[3453],"Acute Heart Failure",[3434,3455,3456],"Dobutamine","Furosemide",{"trials":3458,"activeCount":99},[],{"intervention":3455,"totalTrials":219,"cells":3460},{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3465,"PHASE3":3467,"PHASE4":3469,"NA":3475},{"trials":3462,"activeCount":99},[],{"trials":3464,"activeCount":99},[],{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[],{"trials":3470,"activeCount":99},[3471],{"nctId":3447,"briefTitle":3448,"status":800,"phases":3472,"primaryCompletion":3450,"completion":3451,"start":3450,"enrollment":99,"conditions":3473,"interventions":3474},[90],[3453],[3434,3455,3456],{"trials":3476,"activeCount":99},[],{"intervention":3456,"totalTrials":219,"cells":3478},{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3493},{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[],{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[],{"trials":3488,"activeCount":99},[3489],{"nctId":3447,"briefTitle":3448,"status":800,"phases":3490,"primaryCompletion":3450,"completion":3451,"start":3450,"enrollment":99,"conditions":3491,"interventions":3492},[90],[3453],[3434,3455,3456],{"trials":3494,"activeCount":99},[],{"intervention":3496,"totalTrials":219,"cells":3497},"Oxycodone\u002Facetaminophen",{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3502,"PHASE3":3504,"PHASE4":3506,"NA":3521},{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[],{"trials":3507,"activeCount":99},[3508],{"nctId":3509,"briefTitle":3510,"status":107,"phases":3511,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3516,"interventions":3517},"NCT02455518","Comparative Efficacy of 4 Oral Analgesics",[90],"2016-08","2017-10-04","2015-07",416,[18],[3496,3518,3519,3520],"Hydrocodone\u002Facetaminophen","Codeine\u002Facetaminophen","Ibuprofen\u002Facetaminophen",{"trials":3522,"activeCount":99},[],{"intervention":3518,"totalTrials":219,"cells":3524},{"EARLY_PHASE1":3525,"PHASE1":3527,"PHASE2":3529,"PHASE3":3531,"PHASE4":3533,"NA":3539},{"trials":3526,"activeCount":99},[],{"trials":3528,"activeCount":99},[],{"trials":3530,"activeCount":99},[],{"trials":3532,"activeCount":99},[],{"trials":3534,"activeCount":99},[3535],{"nctId":3509,"briefTitle":3510,"status":107,"phases":3536,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3537,"interventions":3538},[90],[18],[3496,3518,3519,3520],{"trials":3540,"activeCount":99},[],{"intervention":3519,"totalTrials":219,"cells":3542},{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3547,"PHASE3":3549,"PHASE4":3551,"NA":3557},{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":99},[],{"trials":3552,"activeCount":99},[3553],{"nctId":3509,"briefTitle":3510,"status":107,"phases":3554,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3555,"interventions":3556},[90],[18],[3496,3518,3519,3520],{"trials":3558,"activeCount":99},[],{"intervention":3520,"totalTrials":219,"cells":3560},{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3575},{"trials":3562,"activeCount":99},[],{"trials":3564,"activeCount":99},[],{"trials":3566,"activeCount":99},[],{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":99},[3571],{"nctId":3509,"briefTitle":3510,"status":107,"phases":3572,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3573,"interventions":3574},[90],[18],[3496,3518,3519,3520],{"trials":3576,"activeCount":99},[],{"intervention":3578,"totalTrials":219,"cells":3579},"Azithromycin",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3597},{"trials":3581,"activeCount":99},[],{"trials":3583,"activeCount":99},[],{"trials":3585,"activeCount":99},[],{"trials":3587,"activeCount":99},[],{"trials":3589,"activeCount":99},[3590],{"nctId":3591,"briefTitle":3592,"status":257,"phases":3593,"primaryCompletion":3451,"completion":3451,"start":3594,"enrollment":2758,"conditions":3595,"interventions":3596},"NCT02003911","Azithromycin for Children Hospitalized With Asthma",[90],"2013-10",[15],[3578],{"trials":3598,"activeCount":99},[],{"intervention":3600,"totalTrials":219,"cells":3601},"Fluoxetine",{"EARLY_PHASE1":3602,"PHASE1":3604,"PHASE2":3606,"PHASE3":3608,"PHASE4":3610,"NA":3621},{"trials":3603,"activeCount":99},[],{"trials":3605,"activeCount":99},[],{"trials":3607,"activeCount":99},[],{"trials":3609,"activeCount":99},[],{"trials":3611,"activeCount":99},[3612],{"nctId":3613,"briefTitle":3614,"status":107,"phases":3615,"primaryCompletion":388,"completion":388,"start":3616,"enrollment":3617,"conditions":3618,"interventions":3620},"NCT00245635","Fluoxetine in Pediatric Body Dysmorphic Disorder",[90],"2004-11",43,[3619],"Body Dysmorphic Disorder",[3600],{"trials":3622,"activeCount":99},[],{"intervention":2241,"totalTrials":219,"cells":3624},{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3633,"NA":3639},{"trials":3626,"activeCount":99},[],{"trials":3628,"activeCount":99},[],{"trials":3630,"activeCount":99},[],{"trials":3632,"activeCount":99},[],{"trials":3634,"activeCount":99},[3635],{"nctId":2233,"briefTitle":2234,"status":107,"phases":3636,"primaryCompletion":2236,"completion":2236,"start":2237,"enrollment":27,"conditions":3637,"interventions":3638},[90],[2239],[2211,2241],{"trials":3640,"activeCount":99},[],{"intervention":3642,"totalTrials":219,"cells":3643},"NSAID",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3663},{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"trials":3649,"activeCount":99},[],{"trials":3651,"activeCount":99},[],{"trials":3653,"activeCount":99},[3654],{"nctId":3655,"briefTitle":3656,"status":107,"phases":3657,"primaryCompletion":3658,"completion":3658,"start":3659,"enrollment":3660,"conditions":3661,"interventions":3662},"NCT05239767","A Randomized Trial of NSAID Dosing Strategies",[90],"2023-04-24","2022-06-01",407,[1761,21],[3642],{"trials":3664,"activeCount":99},[],{"intervention":3666,"totalTrials":219,"cells":3667},"Dsuvia",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3687},{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[3678],{"nctId":3679,"briefTitle":3680,"status":257,"phases":3681,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":930,"conditions":3685,"interventions":3686},"NCT04716413","Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment",[90],"2022-11-17","2022-11-18","2021-09-27",[21],[3666],{"trials":3688,"activeCount":99},[],{"intervention":3690,"totalTrials":219,"cells":3691},"Bezlotoxumab",{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3696,"PHASE3":3698,"PHASE4":3700,"NA":3711},{"trials":3693,"activeCount":99},[],{"trials":3695,"activeCount":99},[],{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[],{"trials":3701,"activeCount":99},[3702],{"nctId":3703,"briefTitle":3704,"status":257,"phases":3705,"primaryCompletion":3706,"completion":3706,"start":3707,"enrollment":219,"conditions":3708,"interventions":3710},"NCT03937999","Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.",[90],"2022-05-15","2019-08-30",[3709],"Clostridium Difficile",[3690],{"trials":3712,"activeCount":99},[],{"intervention":3714,"totalTrials":219,"cells":3715},"Vitamin D3",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3722,"PHASE4":3724,"NA":3735},{"trials":3717,"activeCount":99},[],{"trials":3719,"activeCount":99},[],{"trials":3721,"activeCount":99},[],{"trials":3723,"activeCount":99},[],{"trials":3725,"activeCount":99},[3726],{"nctId":3727,"briefTitle":3728,"status":107,"phases":3729,"primaryCompletion":2256,"completion":2256,"start":3730,"enrollment":3731,"conditions":3732,"interventions":3734},"NCT01784029","Treatment Study of Vitamin D Deficiency in Adolescents",[90],"2013-02",183,[3733],"Vitamin D Deficiency",[3714],{"trials":3736,"activeCount":99},[],{"intervention":1607,"totalTrials":930,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3753,"PHASE4":3759,"NA":3761},{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[3745,3749],{"nctId":1600,"briefTitle":1601,"status":107,"phases":3746,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":416,"conditions":3747,"interventions":3748},[88],[18],[1607,449],{"nctId":1784,"briefTitle":1785,"status":257,"phases":3750,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":3751,"interventions":3752},[88],[1792],[1766,1607,1794,1795],{"trials":3754,"activeCount":99},[3755],{"nctId":1621,"briefTitle":1622,"status":107,"phases":3756,"primaryCompletion":170,"completion":170,"start":237,"enrollment":1624,"conditions":3757,"interventions":3758},[88,89],[21],[1607,449],{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[],{"intervention":3764,"totalTrials":398,"cells":3765},"Buprenorphine",{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3770,"PHASE3":3783,"PHASE4":3794,"NA":3796},{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[3772],{"nctId":3773,"briefTitle":3774,"status":107,"phases":3775,"primaryCompletion":3776,"completion":3777,"start":3778,"enrollment":3779,"conditions":3780,"interventions":3782},"NCT03150173","Onsite Buprenorphine Treatment at Syringe Exchange Programs",[88],"2023-10-11","2024-03-31","2019-01-02",97,[3781],"Opiate Addiction",[3764],{"trials":3784,"activeCount":99},[3785],{"nctId":3786,"briefTitle":3787,"status":107,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":3409,"conditions":3791,"interventions":3793},"NCT02526212","Buprenorphine Group Medical Visits in Primary Care",[89],"2019-05","2017-01-01",[3792],"Opioid-Related Disorders",[3764],{"trials":3795,"activeCount":99},[],{"trials":3797,"activeCount":99},[],{"intervention":3799,"totalTrials":398,"cells":3800},"Exparel",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3815,"PHASE4":3827,"NA":3829},{"trials":3802,"activeCount":99},[],{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[3807],{"nctId":3808,"briefTitle":3809,"status":257,"phases":3810,"primaryCompletion":3811,"completion":3811,"start":3812,"enrollment":2466,"conditions":3813,"interventions":3814},"NCT03827213","Exparel Interscalene vs Indwelling Catheter",[88],"2021-06-01","2019-01-22",[18],[3799],{"trials":3816,"activeCount":99},[3817],{"nctId":3818,"briefTitle":3819,"status":257,"phases":3820,"primaryCompletion":3821,"completion":3821,"start":3822,"enrollment":3823,"conditions":3824,"interventions":3825},"NCT03303794","0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka",[89],"2018-06-27","2017-10-25",25,[2822],[3799,3826],"0.25% bupivacaine",{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[],{"intervention":3832,"totalTrials":219,"cells":3833},"Chlorhexidine gluconate solution",{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3851,"NA":3853},{"trials":3835,"activeCount":99},[],{"trials":3837,"activeCount":99},[],{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":99},[3842],{"nctId":3843,"briefTitle":3844,"status":107,"phases":3845,"primaryCompletion":3846,"completion":3846,"start":1529,"enrollment":1917,"conditions":3847,"interventions":3849},"NCT03883828","Bacterial Decolonization to Prevent Radiation Dermatitis",[88,89],"2021-12-02",[3848],"Radiation Dermatitis",[3832,3850],"Mupirocin Ointment",{"trials":3852,"activeCount":99},[],{"trials":3854,"activeCount":99},[],{"intervention":3850,"totalTrials":219,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3869,"NA":3871},{"trials":3858,"activeCount":99},[],{"trials":3860,"activeCount":99},[],{"trials":3862,"activeCount":99},[],{"trials":3864,"activeCount":99},[3865],{"nctId":3843,"briefTitle":3844,"status":107,"phases":3866,"primaryCompletion":3846,"completion":3846,"start":1529,"enrollment":1917,"conditions":3867,"interventions":3868},[88,89],[3848],[3832,3850],{"trials":3870,"activeCount":99},[],{"trials":3872,"activeCount":99},[],{"intervention":1619,"totalTrials":219,"cells":3874},{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3887,"NA":3889},{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[3883],{"nctId":1611,"briefTitle":1612,"status":107,"phases":3884,"primaryCompletion":1614,"completion":1614,"start":1615,"enrollment":1616,"conditions":3885,"interventions":3886},[89],[21],[449,1619],{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[],{"intervention":3892,"totalTrials":219,"cells":3893},"Epsilon-aminocaproic acid administered",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3912,"NA":3914},{"trials":3895,"activeCount":99},[],{"trials":3897,"activeCount":99},[],{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[3902],{"nctId":3903,"briefTitle":3904,"status":107,"phases":3905,"primaryCompletion":3906,"completion":3907,"start":1632,"enrollment":334,"conditions":3908,"interventions":3910},"NCT02655653","Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery",[89],"2010-10","2015-10",[3909],"Bleeding",[3892,3911],"Tranexamic Acid administered",{"trials":3913,"activeCount":99},[],{"trials":3915,"activeCount":99},[],{"intervention":3911,"totalTrials":219,"cells":3917},{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3930,"NA":3932},{"trials":3919,"activeCount":99},[],{"trials":3921,"activeCount":99},[],{"trials":3923,"activeCount":99},[],{"trials":3925,"activeCount":99},[3926],{"nctId":3903,"briefTitle":3904,"status":107,"phases":3927,"primaryCompletion":3906,"completion":3907,"start":1632,"enrollment":334,"conditions":3928,"interventions":3929},[89],[3909],[3892,3911],{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":99},[],{"intervention":3935,"totalTrials":219,"cells":3936},"L-carnitine",{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3943,"PHASE4":3958,"NA":3960},{"trials":3938,"activeCount":99},[],{"trials":3940,"activeCount":99},[],{"trials":3942,"activeCount":99},[],{"trials":3944,"activeCount":99},[3945],{"nctId":3946,"briefTitle":3947,"status":107,"phases":3948,"primaryCompletion":3949,"completion":3950,"start":3951,"enrollment":2820,"conditions":3952,"interventions":3956},"NCT01783041","Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants",[88,89],"2020-12","2021-12-28","2013-01",[3953,3954,3955],"Prematurity","Neurodevelopmental Disorder","Carnitine Deficiency",[3935,3957],"5% Dextrose",{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"intervention":3957,"totalTrials":219,"cells":3963},{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3970,"PHASE4":3976,"NA":3978},{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"trials":3969,"activeCount":99},[],{"trials":3971,"activeCount":99},[3972],{"nctId":3946,"briefTitle":3947,"status":107,"phases":3973,"primaryCompletion":3949,"completion":3950,"start":3951,"enrollment":2820,"conditions":3974,"interventions":3975},[88,89],[3953,3954,3955],[3935,3957],{"trials":3977,"activeCount":99},[],{"trials":3979,"activeCount":99},[],{"intervention":337,"totalTrials":219,"cells":3981},{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3988,"PHASE4":3994,"NA":3996},{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[3990],{"nctId":328,"briefTitle":329,"status":107,"phases":3991,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":3992,"interventions":3993},[88,89],[26],[317,337],{"trials":3995,"activeCount":99},[],{"trials":3997,"activeCount":99},[],{"intervention":1966,"totalTrials":219,"cells":3999},{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4012,"NA":4014},{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[4008],{"nctId":1958,"briefTitle":1959,"status":107,"phases":4009,"primaryCompletion":1961,"completion":1961,"start":377,"enrollment":1962,"conditions":4010,"interventions":4011},[89],[1964],[1966,1967,1716,1967,1716,1966],{"trials":4013,"activeCount":99},[],{"trials":4015,"activeCount":99},[],{"intervention":1967,"totalTrials":219,"cells":4017},{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4022,"PHASE3":4024,"PHASE4":4030,"NA":4032},{"trials":4019,"activeCount":99},[],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"trials":4025,"activeCount":99},[4026],{"nctId":1958,"briefTitle":1959,"status":107,"phases":4027,"primaryCompletion":1961,"completion":1961,"start":377,"enrollment":1962,"conditions":4028,"interventions":4029},[89],[1964],[1966,1967,1716,1967,1716,1966],{"trials":4031,"activeCount":99},[],{"trials":4033,"activeCount":99},[],{"intervention":4035,"totalTrials":219,"cells":4036},"Evicel",{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4043,"PHASE4":4053,"NA":4055},{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[],{"trials":4042,"activeCount":99},[],{"trials":4044,"activeCount":99},[4045],{"nctId":4046,"briefTitle":4047,"status":800,"phases":4048,"primaryCompletion":1690,"completion":4049,"start":3907,"enrollment":99,"conditions":4050,"interventions":4052},"NCT02553122","The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty",[89],"2016-12",[4051],"Arthroplasty, Replacement, Knee",[4035],{"trials":4054,"activeCount":99},[],{"trials":4056,"activeCount":99},[],{"intervention":1736,"totalTrials":219,"cells":4058},{"EARLY_PHASE1":4059,"PHASE1":4061,"PHASE2":4063,"PHASE3":4065,"PHASE4":4071,"NA":4073},{"trials":4060,"activeCount":99},[],{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[],{"trials":4066,"activeCount":99},[4067],{"nctId":1728,"briefTitle":1729,"status":107,"phases":4068,"primaryCompletion":965,"completion":965,"start":1731,"enrollment":1732,"conditions":4069,"interventions":4070},[89],[1734],[1736,1648,1737],{"trials":4072,"activeCount":99},[],{"trials":4074,"activeCount":99},[],{"intervention":1737,"totalTrials":219,"cells":4076},{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4083,"PHASE4":4089,"NA":4091},{"trials":4078,"activeCount":99},[],{"trials":4080,"activeCount":99},[],{"trials":4082,"activeCount":99},[],{"trials":4084,"activeCount":99},[4085],{"nctId":1728,"briefTitle":1729,"status":107,"phases":4086,"primaryCompletion":965,"completion":965,"start":1731,"enrollment":1732,"conditions":4087,"interventions":4088},[89],[1734],[1736,1648,1737],{"trials":4090,"activeCount":99},[],{"trials":4092,"activeCount":99},[],{"intervention":4094,"totalTrials":219,"cells":4095},"68Ga-DOTATOC",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4113,"NA":4115},{"trials":4097,"activeCount":99},[],{"trials":4099,"activeCount":99},[],{"trials":4101,"activeCount":99},[],{"trials":4103,"activeCount":99},[4104],{"nctId":4105,"briefTitle":4106,"status":107,"phases":4107,"primaryCompletion":4108,"completion":4108,"start":4109,"enrollment":22,"conditions":4110,"interventions":4112},"NCT03136328","Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET\u002FCT Scan",[89],"2017-03","2016-05-16",[4111],"Neuroendocrine Tumors",[4094],{"trials":4114,"activeCount":99},[],{"trials":4116,"activeCount":99},[],{"intervention":3826,"totalTrials":219,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4131,"NA":4133},{"trials":4120,"activeCount":99},[],{"trials":4122,"activeCount":99},[],{"trials":4124,"activeCount":99},[],{"trials":4126,"activeCount":99},[4127],{"nctId":3818,"briefTitle":3819,"status":257,"phases":4128,"primaryCompletion":3821,"completion":3821,"start":3822,"enrollment":3823,"conditions":4129,"interventions":4130},[89],[2822],[3799,3826],{"trials":4132,"activeCount":99},[],{"trials":4134,"activeCount":99},[],{"intervention":1636,"totalTrials":219,"cells":4136},{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4143,"PHASE4":4149,"NA":4151},{"trials":4138,"activeCount":99},[],{"trials":4140,"activeCount":99},[],{"trials":4142,"activeCount":99},[],{"trials":4144,"activeCount":99},[4145],{"nctId":1628,"briefTitle":1629,"status":107,"phases":4146,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":4147,"interventions":4148},[89],[18],[449,1636],{"trials":4150,"activeCount":99},[],{"trials":4152,"activeCount":99},[],{"intervention":4154,"totalTrials":219,"cells":4155},"EZ scrub vaginal chlorhexidine 4% solution",{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4175,"NA":4177},{"trials":4157,"activeCount":99},[],{"trials":4159,"activeCount":99},[],{"trials":4161,"activeCount":99},[],{"trials":4163,"activeCount":99},[4164],{"nctId":4165,"briefTitle":4166,"status":800,"phases":4167,"primaryCompletion":4168,"completion":4169,"start":4170,"enrollment":99,"conditions":4171,"interventions":4173},"NCT03925155","RCT Investigating Pre-cesarean Vaginal Wash of Chlorhexidine vs Povidone-iodine for Patient With Ruptured Amniotic Membrane.",[89],"2022-05-01","2023-05-01","2020-05-01",[4172],"Cesarean Section Complications",[4154,4174],"10% provodine-iodine vaginal preparation",{"trials":4176,"activeCount":99},[],{"trials":4178,"activeCount":99},[],{"intervention":4174,"totalTrials":219,"cells":4180},{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4193,"NA":4195},{"trials":4182,"activeCount":99},[],{"trials":4184,"activeCount":99},[],{"trials":4186,"activeCount":99},[],{"trials":4188,"activeCount":99},[4189],{"nctId":4165,"briefTitle":4166,"status":800,"phases":4190,"primaryCompletion":4168,"completion":4169,"start":4170,"enrollment":99,"conditions":4191,"interventions":4192},[89],[4172],[4154,4174],{"trials":4194,"activeCount":99},[],{"trials":4196,"activeCount":99},[],{"intervention":4198,"totalTrials":219,"cells":4199},"Intranasal fentanyl",{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4217,"NA":4219},{"trials":4201,"activeCount":99},[],{"trials":4203,"activeCount":99},[],{"trials":4205,"activeCount":99},[],{"trials":4207,"activeCount":99},[4208],{"nctId":4209,"briefTitle":4210,"status":107,"phases":4211,"primaryCompletion":3117,"completion":3117,"start":4212,"enrollment":4213,"conditions":4214,"interventions":4216},"NCT03872700","Intranasal Fentanyl as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage",[89],"2019-08-01",49,[4215],"Abscess",[4198],{"trials":4218,"activeCount":99},[],{"trials":4220,"activeCount":99},[],{"intervention":4222,"totalTrials":219,"cells":4223},"H2O",{"EARLY_PHASE1":4224,"PHASE1":4226,"PHASE2":4228,"PHASE3":4230,"PHASE4":4241,"NA":4243},{"trials":4225,"activeCount":99},[],{"trials":4227,"activeCount":99},[],{"trials":4229,"activeCount":99},[],{"trials":4231,"activeCount":99},[4232],{"nctId":4233,"briefTitle":4234,"status":107,"phases":4235,"primaryCompletion":4236,"completion":4236,"start":4237,"enrollment":1633,"conditions":4238,"interventions":4239},"NCT01311895","Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone",[89],"2011-11","2011-01",[21],[4222,4240],"1+1",{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[],{"intervention":4240,"totalTrials":219,"cells":4246},{"EARLY_PHASE1":4247,"PHASE1":4249,"PHASE2":4251,"PHASE3":4253,"PHASE4":4259,"NA":4261},{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[],{"trials":4252,"activeCount":99},[],{"trials":4254,"activeCount":99},[4255],{"nctId":4233,"briefTitle":4234,"status":107,"phases":4256,"primaryCompletion":4236,"completion":4236,"start":4237,"enrollment":1633,"conditions":4257,"interventions":4258},[89],[21],[4222,4240],{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"intervention":129,"totalTrials":219,"cells":4264},{"EARLY_PHASE1":4265,"PHASE1":4267,"PHASE2":4269,"PHASE3":4271,"PHASE4":4277,"NA":4279},{"trials":4266,"activeCount":99},[],{"trials":4268,"activeCount":99},[],{"trials":4270,"activeCount":99},[],{"trials":4272,"activeCount":99},[4273],{"nctId":120,"briefTitle":121,"status":107,"phases":4274,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":4275,"interventions":4276},[89],[24],[128,128,128,129],{"trials":4278,"activeCount":99},[],{"trials":4280,"activeCount":99},[],{"intervention":4282,"totalTrials":219,"cells":4283},"Pregabalin",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4300,"NA":4302},{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[4292],{"nctId":4293,"briefTitle":4294,"status":257,"phases":4295,"primaryCompletion":189,"completion":189,"start":4296,"enrollment":930,"conditions":4297,"interventions":4299},"NCT03031340","Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae",[89],"2012-05",[4298],"Spinal Fusion",[4282],{"trials":4301,"activeCount":99},[],{"trials":4303,"activeCount":99},[],{"intervention":4305,"totalTrials":219,"cells":4306},"Intramuscular methylprednisolone acetate",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4324,"NA":4326},{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":99},[],{"trials":4312,"activeCount":99},[],{"trials":4314,"activeCount":99},[4315],{"nctId":4316,"briefTitle":4317,"status":107,"phases":4318,"primaryCompletion":1665,"completion":1665,"start":4319,"enrollment":4320,"conditions":4321,"interventions":4323},"NCT00290589","A Trial of Corticosteroids for Low Back Pain",[89],"2003-06",82,[4322],"Radicular Low Back Pain",[4305],{"trials":4325,"activeCount":99},[],{"trials":4327,"activeCount":99},[],{"intervention":2107,"totalTrials":398,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4336,"PHASE2":4338,"PHASE3":4355,"PHASE4":4357,"NA":4359},{"trials":4331,"activeCount":99},[4332],{"nctId":2094,"briefTitle":2095,"status":257,"phases":4333,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":4334,"interventions":4335},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[4340],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4343,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4346,"interventions":4348},"NCT00002461","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma",[88],"1991-07","1988-04",[4347],"Lymphoma",[4349,4350,4351,4352,4353,4354],"filgrastim","sargramostim","carmustine","cisplatin","cyclophosphamide","etoposide",{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[],{"intervention":4349,"totalTrials":398,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4367,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4364,"activeCount":99},[],{"trials":4366,"activeCount":99},[],{"trials":4368,"activeCount":99},[4369,4373],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4370,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4371,"interventions":4372},[88],[4347],[4349,4350,4351,4352,4353,4354],{"nctId":4374,"briefTitle":4375,"status":107,"phases":4376,"primaryCompletion":4377,"completion":4377,"start":4378,"enrollment":1587,"conditions":4379,"interventions":4385},"NCT00019474","Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer",[88],"2000-08","1998-03",[4380,4381,4382,4383,267,4384],"Extrahepatic Bile Duct Cancer","Gastric Cancer","Gastrointestinal Carcinoid Tumor","Liver Cancer","Small Intestine Cancer",[4349,4386,4387,4388],"recombinant interferon alfa","fluorouracil","hydroxyurea",{"trials":4390,"activeCount":99},[],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"intervention":4352,"totalTrials":398,"cells":4396},{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4419,"PHASE4":4421,"NA":4423},{"trials":4398,"activeCount":99},[],{"trials":4400,"activeCount":99},[],{"trials":4402,"activeCount":99},[4403,4407],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4404,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4405,"interventions":4406},[88],[4347],[4349,4350,4351,4352,4353,4354],{"nctId":4408,"briefTitle":4409,"status":107,"phases":4410,"primaryCompletion":4411,"completion":4411,"start":4412,"enrollment":4413,"conditions":4414,"interventions":4416},"NCT00231842","Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus",[88],"2011-07","2003-02",30,[4415],"Uterine Cancer",[4417,4418],"Ifosfamide","Cisplatin",{"trials":4420,"activeCount":99},[],{"trials":4422,"activeCount":99},[],{"trials":4424,"activeCount":99},[],{"intervention":4426,"totalTrials":398,"cells":4427},"ixabepilone",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4442,"PHASE3":4452,"PHASE4":4454,"NA":4456},{"trials":4429,"activeCount":99},[],{"trials":4431,"activeCount":99},[4432],{"nctId":4433,"briefTitle":4434,"status":107,"phases":4435,"primaryCompletion":4436,"completion":4436,"start":4437,"enrollment":9,"conditions":4438,"interventions":4440},"NCT00096317","Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors",[87],"2005-12-05","2003-03",[4439],"Unspecified Adult Solid Tumor, Protocol Specific",[4426,4441],"ketoconazole",{"trials":4443,"activeCount":99},[4444],{"nctId":4445,"briefTitle":4446,"status":107,"phases":4447,"primaryCompletion":2237,"start":3616,"conditions":4448,"interventions":4451},"NCT00030706","Ixabepilone in Treating Patients With Relapsed and\u002For Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer",[88],[4449,4450],"Ovarian Cancer","Peritoneal Cavity Cancer",[4426],{"trials":4453,"activeCount":99},[],{"trials":4455,"activeCount":99},[],{"trials":4457,"activeCount":99},[],{"intervention":4459,"totalTrials":219,"cells":4460},"Topotecan and Taxotere",{"EARLY_PHASE1":4461,"PHASE1":4463,"PHASE2":4465,"PHASE3":4475,"PHASE4":4477,"NA":4479},{"trials":4462,"activeCount":99},[],{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[4467],{"nctId":4468,"briefTitle":4469,"status":107,"phases":4470,"completion":170,"start":3616,"enrollment":2173,"conditions":4471,"interventions":4474},"NCT00231855","Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers",[88],[4472,4473],"Ovarian Neoplasms","Uterine Neoplasms",[4459],{"trials":4476,"activeCount":99},[],{"trials":4478,"activeCount":99},[],{"trials":4480,"activeCount":99},[],{"intervention":4482,"totalTrials":219,"cells":4483},"Chlorhexidine gluconate",{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4500,"PHASE4":4502,"NA":4504},{"trials":4485,"activeCount":99},[],{"trials":4487,"activeCount":99},[],{"trials":4489,"activeCount":99},[4490],{"nctId":4491,"briefTitle":4492,"status":257,"phases":4493,"primaryCompletion":4494,"completion":4494,"start":4495,"enrollment":19,"conditions":4496,"interventions":4498},"NCT02598778","Comparing Mouth Rinses (and Chewing Gum) in Regard to Streptococcus Mutans Reduction",[88],"2016-04-01","2015-11-01",[4497],"Dental Caries",[4482,4499],"Sodium Fluoride",{"trials":4501,"activeCount":99},[],{"trials":4503,"activeCount":99},[],{"trials":4505,"activeCount":99},[],{"intervention":4499,"totalTrials":219,"cells":4507},{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[4514],{"nctId":4491,"briefTitle":4492,"status":257,"phases":4515,"primaryCompletion":4494,"completion":4494,"start":4495,"enrollment":19,"conditions":4516,"interventions":4517},[88],[4497],[4482,4499],{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"intervention":4525,"totalTrials":219,"cells":4526},"Fecal microbiota transplantation",{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4531,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4528,"activeCount":99},[],{"trials":4530,"activeCount":99},[],{"trials":4532,"activeCount":99},[4533],{"nctId":4534,"briefTitle":4535,"status":107,"phases":4536,"primaryCompletion":2757,"completion":4537,"start":4538,"enrollment":4539,"conditions":4540,"interventions":4542},"NCT02328547","Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome",[88],"2018-03","2015-05",48,[4541],"Irritable Bowel Syndrome",[4525],{"trials":4544,"activeCount":99},[],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[],{"intervention":4550,"totalTrials":219,"cells":4551},"Rilonacept",{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4553,"activeCount":99},[],{"trials":4555,"activeCount":99},[],{"trials":4557,"activeCount":99},[4558],{"nctId":4559,"briefTitle":4560,"status":107,"phases":4561,"primaryCompletion":1673,"completion":1673,"start":4562,"enrollment":4563,"conditions":4564,"interventions":4566},"NCT00534495","Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults",[88],"2008-11",71,[4565],"Juvenile Idiopathic Arthritis",[4550],{"trials":4568,"activeCount":99},[],{"trials":4570,"activeCount":99},[],{"trials":4572,"activeCount":99},[],{"intervention":4574,"totalTrials":219,"cells":4575},"Necitumumab-Gemcitabine-Cisplatin",{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4592,"PHASE4":4594,"NA":4596},{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[],{"trials":4581,"activeCount":99},[4582],{"nctId":4583,"briefTitle":4584,"status":257,"phases":4585,"primaryCompletion":4586,"completion":4587,"start":4588,"enrollment":219,"conditions":4589,"interventions":4591},"NCT03574818","Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001",[88],"2018-10-25","2019-09-26","2018-05-29",[4590],"Squamous Cell Lung Cancer",[4574],{"trials":4593,"activeCount":99},[],{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[],{"intervention":4599,"totalTrials":219,"cells":4600},"PembroRT",{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4602,"activeCount":99},[],{"trials":4604,"activeCount":99},[],{"trials":4606,"activeCount":99},[4607],{"nctId":4608,"briefTitle":4609,"status":107,"phases":4610,"primaryCompletion":3683,"completion":3683,"start":4611,"enrollment":3823,"conditions":4612,"interventions":4614},"NCT03523702","The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial",[88],"2018-08-30",[4613],"Non-small Cell Lung Cancer, NSCLC",[4599],{"trials":4616,"activeCount":99},[],{"trials":4618,"activeCount":99},[],{"trials":4620,"activeCount":99},[],{"intervention":4622,"totalTrials":219,"cells":4623},"BNT162b2 vaccine",{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4641,"PHASE4":4643,"NA":4645},{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[4630],{"nctId":4631,"briefTitle":4632,"status":257,"phases":4633,"primaryCompletion":4634,"completion":4635,"start":4636,"enrollment":4637,"conditions":4638,"interventions":4640},"NCT05016622","Booster Dose Trial",[88],"2022-04-20","2023-05-21","2021-08-10",106,[4639],"Cancer",[4622],{"trials":4642,"activeCount":99},[],{"trials":4644,"activeCount":99},[],{"trials":4646,"activeCount":99},[],{"intervention":2177,"totalTrials":219,"cells":4648},{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4653,"PHASE3":4659,"PHASE4":4661,"NA":4663},{"trials":4650,"activeCount":99},[],{"trials":4652,"activeCount":99},[],{"trials":4654,"activeCount":99},[4655],{"nctId":2168,"briefTitle":2169,"status":107,"phases":4656,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":2173,"conditions":4657,"interventions":4658},[88],[2175],[2177,2134],{"trials":4660,"activeCount":99},[],{"trials":4662,"activeCount":99},[],{"trials":4664,"activeCount":99},[],{"intervention":4666,"totalTrials":219,"cells":4667},"Bacterial decolonization",{"EARLY_PHASE1":4668,"PHASE1":4670,"PHASE2":4672,"PHASE3":4684,"PHASE4":4686,"NA":4688},{"trials":4669,"activeCount":99},[],{"trials":4671,"activeCount":99},[],{"trials":4673,"activeCount":99},[4674],{"nctId":4675,"briefTitle":4676,"status":800,"phases":4677,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":99,"conditions":4680,"interventions":4681},"NCT05505214","Topical Steroids & Bacterial Decolonization for Radiation Dermatitis",[88],"2025-09-01","2023-09-01",[3848],[4666,4682,4683],"Mometasone furoate 0.1% cream","Bacterial decolonization and Mometasone furoate 0.1% cream",{"trials":4685,"activeCount":99},[],{"trials":4687,"activeCount":99},[],{"trials":4689,"activeCount":99},[],{"intervention":4682,"totalTrials":219,"cells":4691},{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4702,"PHASE4":4704,"NA":4706},{"trials":4693,"activeCount":99},[],{"trials":4695,"activeCount":99},[],{"trials":4697,"activeCount":99},[4698],{"nctId":4675,"briefTitle":4676,"status":800,"phases":4699,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":99,"conditions":4700,"interventions":4701},[88],[3848],[4666,4682,4683],{"trials":4703,"activeCount":99},[],{"trials":4705,"activeCount":99},[],{"trials":4707,"activeCount":99},[],{"intervention":4683,"totalTrials":219,"cells":4709},{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4711,"activeCount":99},[],{"trials":4713,"activeCount":99},[],{"trials":4715,"activeCount":99},[4716],{"nctId":4675,"briefTitle":4676,"status":800,"phases":4717,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":99,"conditions":4718,"interventions":4719},[88],[3848],[4666,4682,4683],{"trials":4721,"activeCount":99},[],{"trials":4723,"activeCount":99},[],{"trials":4725,"activeCount":99},[],{"intervention":4727,"totalTrials":219,"cells":4728},"Ropivacaine 0.5% 20cc injectate bilaterally",{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4742,"PHASE4":4744,"NA":4746},{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[4735],{"nctId":4736,"briefTitle":4737,"status":257,"phases":4738,"primaryCompletion":4739,"completion":4739,"start":180,"enrollment":1138,"conditions":4740,"interventions":4741},"NCT01866917","Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women",[87,88],"2016-04",[18],[4727],{"trials":4743,"activeCount":99},[],{"trials":4745,"activeCount":99},[],{"trials":4747,"activeCount":99},[],{"intervention":4749,"totalTrials":219,"cells":4750},"2 mg IV hydromorphone",{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4755,"PHASE3":4766,"PHASE4":4768,"NA":4770},{"trials":4752,"activeCount":99},[],{"trials":4754,"activeCount":99},[],{"trials":4756,"activeCount":99},[4757],{"nctId":4758,"briefTitle":4759,"status":107,"phases":4760,"primaryCompletion":4761,"completion":4761,"start":4762,"enrollment":4763,"conditions":4764,"interventions":4765},"NCT00305110","Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain",[88],"2006-10","2006-01",298,[21],[4749],{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"intervention":4773,"totalTrials":219,"cells":4774},"Melatonin 10 MG",{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4792,"PHASE4":4794,"NA":4796},{"trials":4776,"activeCount":99},[],{"trials":4778,"activeCount":99},[],{"trials":4780,"activeCount":99},[4781],{"nctId":4782,"briefTitle":4783,"status":107,"phases":4784,"primaryCompletion":4785,"completion":4786,"start":4787,"enrollment":1587,"conditions":4788,"interventions":4790},"NCT04791943","Preoperative Melatonin to Decrease Analgesia Usage After Third Molar Surgery",[88],"2025-10-01","2025-10-20","2021-11-16",[282,4789],"Narcotic Use",[4773,4791],"Lactose pill",{"trials":4793,"activeCount":99},[],{"trials":4795,"activeCount":99},[],{"trials":4797,"activeCount":99},[],{"intervention":4791,"totalTrials":219,"cells":4799},{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4804,"PHASE3":4810,"PHASE4":4812,"NA":4814},{"trials":4801,"activeCount":99},[],{"trials":4803,"activeCount":99},[],{"trials":4805,"activeCount":99},[4806],{"nctId":4782,"briefTitle":4783,"status":107,"phases":4807,"primaryCompletion":4785,"completion":4786,"start":4787,"enrollment":1587,"conditions":4808,"interventions":4809},[88],[282,4789],[4773,4791],{"trials":4811,"activeCount":99},[],{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"intervention":4817,"totalTrials":219,"cells":4818},"Carboplatin and Paclitaxel and Pelvic Radiation Therapy",{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4823,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4820,"activeCount":99},[],{"trials":4822,"activeCount":99},[],{"trials":4824,"activeCount":99},[4825],{"nctId":4826,"briefTitle":4827,"status":107,"phases":4828,"primaryCompletion":4411,"completion":4411,"start":4829,"enrollment":4830,"conditions":4831,"interventions":4832},"NCT00231868","A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma",[88],"2001-12",81,[4415],[4817,4833],"Carboplatin and Paclitaxel and Radiation Therapy",{"trials":4835,"activeCount":99},[],{"trials":4837,"activeCount":99},[],{"trials":4839,"activeCount":99},[],{"intervention":4833,"totalTrials":219,"cells":4841},{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4843,"activeCount":99},[],{"trials":4845,"activeCount":99},[],{"trials":4847,"activeCount":99},[4848],{"nctId":4826,"briefTitle":4827,"status":107,"phases":4849,"primaryCompletion":4411,"completion":4411,"start":4829,"enrollment":4830,"conditions":4850,"interventions":4851},[88],[4415],[4817,4833],{"trials":4853,"activeCount":99},[],{"trials":4855,"activeCount":99},[],{"trials":4857,"activeCount":99},[],{"intervention":4859,"totalTrials":219,"cells":4860},"Divalproex sodium",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4865,"PHASE3":4876,"PHASE4":4878,"NA":4880},{"trials":4862,"activeCount":99},[],{"trials":4864,"activeCount":99},[],{"trials":4866,"activeCount":99},[4867],{"nctId":4868,"briefTitle":4869,"status":107,"phases":4870,"primaryCompletion":4871,"completion":4871,"start":4872,"enrollment":4873,"conditions":4874,"interventions":4875},"NCT00211757","Divalproex Sodium vs. Placebo in Childhood\u002FAdolescent Autism",[88],"2008-07","2002-09",27,[3010],[4859],{"trials":4877,"activeCount":99},[],{"trials":4879,"activeCount":99},[],{"trials":4881,"activeCount":99},[],{"intervention":4350,"totalTrials":219,"cells":4883},{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4894,"PHASE4":4896,"NA":4898},{"trials":4885,"activeCount":99},[],{"trials":4887,"activeCount":99},[],{"trials":4889,"activeCount":99},[4890],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4891,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4892,"interventions":4893},[88],[4347],[4349,4350,4351,4352,4353,4354],{"trials":4895,"activeCount":99},[],{"trials":4897,"activeCount":99},[],{"trials":4899,"activeCount":99},[],{"intervention":4351,"totalTrials":219,"cells":4901},{"EARLY_PHASE1":4902,"PHASE1":4904,"PHASE2":4906,"PHASE3":4912,"PHASE4":4914,"NA":4916},{"trials":4903,"activeCount":99},[],{"trials":4905,"activeCount":99},[],{"trials":4907,"activeCount":99},[4908],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4909,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4910,"interventions":4911},[88],[4347],[4349,4350,4351,4352,4353,4354],{"trials":4913,"activeCount":99},[],{"trials":4915,"activeCount":99},[],{"trials":4917,"activeCount":99},[],{"intervention":4353,"totalTrials":219,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4924,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4921,"activeCount":99},[],{"trials":4923,"activeCount":99},[],{"trials":4925,"activeCount":99},[4926],{"nctId":4341,"briefTitle":4342,"status":107,"phases":4927,"primaryCompletion":4344,"completion":4344,"start":4345,"enrollment":1138,"conditions":4928,"interventions":4929},[88],[4347],[4349,4350,4351,4352,4353,4354],{"trials":4931,"activeCount":99},[],{"trials":4933,"activeCount":99},[],{"trials":4935,"activeCount":99},[],{"intervention":4417,"totalTrials":219,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":99},[],{"trials":4941,"activeCount":99},[],{"trials":4943,"activeCount":99},[4944],{"nctId":4408,"briefTitle":4409,"status":107,"phases":4945,"primaryCompletion":4411,"completion":4411,"start":4412,"enrollment":4413,"conditions":4946,"interventions":4947},[88],[4415],[4417,4418],{"trials":4949,"activeCount":99},[],{"trials":4951,"activeCount":99},[],{"trials":4953,"activeCount":99},[],{"intervention":4955,"totalTrials":219,"cells":4956},"Risedronate",{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4961,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4958,"activeCount":99},[],{"trials":4960,"activeCount":99},[],{"trials":4962,"activeCount":99},[4963],{"nctId":4964,"briefTitle":4965,"status":107,"phases":4966,"primaryCompletion":4871,"completion":4871,"start":4967,"enrollment":1587,"conditions":4968,"interventions":4970},"NCT00266708","Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.",[87,88],"2002-10",[4969],"Renal Transplant Osteodystrophy",[4955],{"trials":4972,"activeCount":99},[],{"trials":4974,"activeCount":99},[],{"trials":4976,"activeCount":99},[],{"intervention":4978,"totalTrials":219,"cells":4979},"Cinacalcet HCl",{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4981,"activeCount":99},[],{"trials":4983,"activeCount":99},[],{"trials":4985,"activeCount":99},[4986],{"nctId":4987,"briefTitle":4988,"status":257,"phases":4989,"primaryCompletion":191,"completion":191,"start":4990,"enrollment":1457,"conditions":4991,"interventions":4994},"NCT00415584","Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients",[87,88],"2007-02-09",[4992,4993],"Secondary Hyperparathyroidism","Hypercalcemia",[4978],{"trials":4996,"activeCount":99},[],{"trials":4998,"activeCount":99},[],{"trials":5000,"activeCount":99},[],{"intervention":5002,"totalTrials":219,"cells":5003},"Acetaminophen 1000mg IV",{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5019,"PHASE4":5021,"NA":5023},{"trials":5005,"activeCount":99},[],{"trials":5007,"activeCount":99},[],{"trials":5009,"activeCount":99},[5010],{"nctId":5011,"briefTitle":5012,"status":107,"phases":5013,"primaryCompletion":5014,"completion":965,"start":5015,"enrollment":250,"conditions":5016,"interventions":5017},"NCT03521102","Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED",[88],"2021-10-30","2018-08-20",[21],[5002,5018],"Hydromorphone 0.5 mg IV",{"trials":5020,"activeCount":99},[],{"trials":5022,"activeCount":99},[],{"trials":5024,"activeCount":99},[],{"intervention":5018,"totalTrials":219,"cells":5026},{"EARLY_PHASE1":5027,"PHASE1":5029,"PHASE2":5031,"PHASE3":5037,"PHASE4":5039,"NA":5041},{"trials":5028,"activeCount":99},[],{"trials":5030,"activeCount":99},[],{"trials":5032,"activeCount":99},[5033],{"nctId":5011,"briefTitle":5012,"status":107,"phases":5034,"primaryCompletion":5014,"completion":965,"start":5015,"enrollment":250,"conditions":5035,"interventions":5036},[88],[21],[5002,5018],{"trials":5038,"activeCount":99},[],{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[],{"intervention":5044,"totalTrials":219,"cells":5045},"Hydroxychloroquine",{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5050,"PHASE3":5063,"PHASE4":5065,"NA":5067},{"trials":5047,"activeCount":99},[],{"trials":5049,"activeCount":99},[],{"trials":5051,"activeCount":99},[5052],{"nctId":5053,"briefTitle":5054,"status":800,"phases":5055,"primaryCompletion":5056,"completion":5056,"start":5057,"enrollment":99,"conditions":5058,"interventions":5062},"NCT04350450","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore",[88],"2020-08","2020-04",[5059,5060,5061],"COVID","Coronavirus","COVID-19",[5044],{"trials":5064,"activeCount":99},[],{"trials":5066,"activeCount":99},[],{"trials":5068,"activeCount":99},[],{"intervention":5070,"totalTrials":219,"cells":5071},"EMLA Cream",{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5073,"activeCount":99},[],{"trials":5075,"activeCount":99},[],{"trials":5077,"activeCount":99},[5078],{"nctId":5079,"briefTitle":5080,"status":107,"phases":5081,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":1225,"conditions":5084,"interventions":5086},"NCT00530803","The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children",[88],"2009-01","2007-06",[18,5085],"Needle Phobia",[5070,5087],"Synera Patch",{"trials":5089,"activeCount":99},[],{"trials":5091,"activeCount":99},[],{"trials":5093,"activeCount":99},[],{"intervention":5087,"totalTrials":219,"cells":5095},{"EARLY_PHASE1":5096,"PHASE1":5098,"PHASE2":5100,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5097,"activeCount":99},[],{"trials":5099,"activeCount":99},[],{"trials":5101,"activeCount":99},[5102],{"nctId":5079,"briefTitle":5080,"status":107,"phases":5103,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":1225,"conditions":5104,"interventions":5105},[88],[18,5085],[5070,5087],{"trials":5107,"activeCount":99},[],{"trials":5109,"activeCount":99},[],{"trials":5111,"activeCount":99},[],{"intervention":2227,"totalTrials":219,"cells":5113},{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5118,"PHASE3":5124,"PHASE4":5126,"NA":5128},{"trials":5115,"activeCount":99},[],{"trials":5117,"activeCount":99},[],{"trials":5119,"activeCount":99},[5120],{"nctId":2220,"briefTitle":2221,"status":107,"phases":5121,"primaryCompletion":2223,"completion":2223,"start":170,"enrollment":22,"conditions":5122,"interventions":5123},[88],[2225],[2227,2211],{"trials":5125,"activeCount":99},[],{"trials":5127,"activeCount":99},[],{"trials":5129,"activeCount":99},[],{"intervention":5131,"totalTrials":219,"cells":5132},"Acarbose",{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5149,"PHASE4":5151,"NA":5153},{"trials":5134,"activeCount":99},[],{"trials":5136,"activeCount":99},[],{"trials":5138,"activeCount":99},[5139],{"nctId":5140,"briefTitle":5141,"status":257,"phases":5142,"primaryCompletion":5143,"completion":5144,"start":5145,"enrollment":1813,"conditions":5146,"interventions":5148},"NCT02953093","Study of Acarbose in Longevity",[88],"2019-04-20","2019-12-26","2017-08-30",[5147],"Aging",[5131],{"trials":5150,"activeCount":99},[],{"trials":5152,"activeCount":99},[],{"trials":5154,"activeCount":99},[],{"intervention":4386,"totalTrials":219,"cells":5156},{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5161,"PHASE3":5167,"PHASE4":5169,"NA":5171},{"trials":5158,"activeCount":99},[],{"trials":5160,"activeCount":99},[],{"trials":5162,"activeCount":99},[5163],{"nctId":4374,"briefTitle":4375,"status":107,"phases":5164,"primaryCompletion":4377,"completion":4377,"start":4378,"enrollment":1587,"conditions":5165,"interventions":5166},[88],[4380,4381,4382,4383,267,4384],[4349,4386,4387,4388],{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[],{"trials":5172,"activeCount":99},[],{"intervention":4387,"totalTrials":219,"cells":5174},{"EARLY_PHASE1":5175,"PHASE1":5177,"PHASE2":5179,"PHASE3":5185,"PHASE4":5187,"NA":5189},{"trials":5176,"activeCount":99},[],{"trials":5178,"activeCount":99},[],{"trials":5180,"activeCount":99},[5181],{"nctId":4374,"briefTitle":4375,"status":107,"phases":5182,"primaryCompletion":4377,"completion":4377,"start":4378,"enrollment":1587,"conditions":5183,"interventions":5184},[88],[4380,4381,4382,4383,267,4384],[4349,4386,4387,4388],{"trials":5186,"activeCount":99},[],{"trials":5188,"activeCount":99},[],{"trials":5190,"activeCount":99},[],{"intervention":4388,"totalTrials":219,"cells":5192},{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5203,"PHASE4":5205,"NA":5207},{"trials":5194,"activeCount":99},[],{"trials":5196,"activeCount":99},[],{"trials":5198,"activeCount":99},[5199],{"nctId":4374,"briefTitle":4375,"status":107,"phases":5200,"primaryCompletion":4377,"completion":4377,"start":4378,"enrollment":1587,"conditions":5201,"interventions":5202},[88],[4380,4381,4382,4383,267,4384],[4349,4386,4387,4388],{"trials":5204,"activeCount":99},[],{"trials":5206,"activeCount":99},[],{"trials":5208,"activeCount":99},[],{"intervention":5210,"totalTrials":219,"cells":5211},"Pasireotide 0.6Mg Solution for",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5216,"PHASE3":5229,"PHASE4":5231,"NA":5233},{"trials":5213,"activeCount":99},[],{"trials":5215,"activeCount":99},[],{"trials":5217,"activeCount":99},[5218],{"nctId":5219,"briefTitle":5220,"status":800,"phases":5221,"primaryCompletion":1811,"completion":5222,"start":344,"enrollment":99,"conditions":5223,"interventions":5227},"NCT03053284","Pasireotide in Hyperinsulinemic Hypoglycemia",[88],"2018-04",[5224,5225,5226],"Congenital Hyperinsulinism","Insulinoma","Hyperinsulinism",[5210,5228],"Saline Solution",{"trials":5230,"activeCount":99},[],{"trials":5232,"activeCount":99},[],{"trials":5234,"activeCount":99},[],{"intervention":5228,"totalTrials":219,"cells":5236},{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5247,"PHASE4":5249,"NA":5251},{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[5243],{"nctId":5219,"briefTitle":5220,"status":800,"phases":5244,"primaryCompletion":1811,"completion":5222,"start":344,"enrollment":99,"conditions":5245,"interventions":5246},[88],[5224,5225,5226],[5210,5228],{"trials":5248,"activeCount":99},[],{"trials":5250,"activeCount":99},[],{"trials":5252,"activeCount":99},[],{"intervention":1921,"totalTrials":219,"cells":5254},{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5256,"activeCount":99},[],{"trials":5258,"activeCount":99},[],{"trials":5260,"activeCount":99},[5261],{"nctId":1913,"briefTitle":1914,"status":107,"phases":5262,"primaryCompletion":1614,"completion":1916,"start":170,"enrollment":1917,"conditions":5263,"interventions":5264},[88],[1919],[1921,1904],{"trials":5266,"activeCount":99},[],{"trials":5268,"activeCount":99},[],{"trials":5270,"activeCount":99},[],{"intervention":5272,"totalTrials":219,"cells":5273},"Lovastatin",{"EARLY_PHASE1":5274,"PHASE1":5276,"PHASE2":5278,"PHASE3":5288,"PHASE4":5290,"NA":5292},{"trials":5275,"activeCount":99},[],{"trials":5277,"activeCount":99},[],{"trials":5279,"activeCount":99},[5280],{"nctId":5281,"briefTitle":5282,"status":107,"phases":5283,"primaryCompletion":5284,"completion":5284,"start":3514,"enrollment":1530,"conditions":5285,"interventions":5287},"NCT02563860","Pharmacological Treatment of Rett Syndrome With Statins",[88],"2016-07",[5286],"Rett Syndrome",[5272],{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[],{"trials":5293,"activeCount":99},[],{"intervention":5295,"totalTrials":219,"cells":5296},"Tarceva",{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5298,"activeCount":99},[],{"trials":5300,"activeCount":99},[],{"trials":5302,"activeCount":99},[5303],{"nctId":5304,"briefTitle":5305,"status":107,"phases":5306,"primaryCompletion":5307,"completion":5307,"start":5308,"enrollment":4413,"conditions":5309,"interventions":5311},"NCT00200395","OSI-774 (Erlotinib, Tarceva) in Elderly Patients",[88],"2007-01-12","2003-07-02",[5310],"Non-Small Cell Lung Cancer",[5295],{"trials":5313,"activeCount":99},[],{"trials":5315,"activeCount":99},[],{"trials":5317,"activeCount":99},[],{"intervention":5319,"totalTrials":219,"cells":5320},"Glatiramer Acetate",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5335,"PHASE4":5337,"NA":5339},{"trials":5322,"activeCount":99},[],{"trials":5324,"activeCount":99},[],{"trials":5326,"activeCount":99},[5327],{"nctId":5328,"briefTitle":5329,"status":107,"phases":5330,"primaryCompletion":5331,"completion":5332,"start":2287,"enrollment":95,"conditions":5333,"interventions":5334},"NCT02153723","Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)",[88],"2014-08","2016-01",[5286],[5319],{"trials":5336,"activeCount":99},[],{"trials":5338,"activeCount":99},[],{"trials":5340,"activeCount":99},[],{"intervention":5342,"totalTrials":219,"cells":5343},"Carvedilol",{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5361,"PHASE4":5363,"NA":5365},{"trials":5345,"activeCount":99},[],{"trials":5347,"activeCount":99},[],{"trials":5349,"activeCount":99},[5350],{"nctId":5351,"briefTitle":5352,"status":5353,"phases":5354,"primaryCompletion":5355,"completion":5356,"start":5357,"enrollment":2575,"conditions":5358,"interventions":5360},"NCT02944201","Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate","UNKNOWN",[88],"2020-12-31","2021-12-31","2017-04-01",[5359],"Prostate Cancer",[5342],{"trials":5362,"activeCount":99},[],{"trials":5364,"activeCount":99},[],{"trials":5366,"activeCount":99},[],{"intervention":5368,"totalTrials":219,"cells":5369},"1% chloroprocaine",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5371,"activeCount":99},[],{"trials":5373,"activeCount":99},[],{"trials":5375,"activeCount":99},[5376],{"nctId":5377,"briefTitle":5378,"status":107,"phases":5379,"primaryCompletion":5380,"completion":5380,"start":5381,"enrollment":5382,"conditions":5383,"interventions":5387},"NCT03324984","1% Chloroprocaine(PF) vs. Bupivacaine Spinals",[88],"2023-02-01","2019-09-11",110,[5384,5385,5386],"Return of Motor and Sensory Blockade","Anesthesia, Spinal","Decrease Discharge Time Status Post Hemorrhoidectomy",[5368,5388],"0.75% bupivacaine",{"trials":5390,"activeCount":99},[],{"trials":5392,"activeCount":99},[],{"trials":5394,"activeCount":99},[],{"intervention":5388,"totalTrials":219,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5407,"PHASE4":5409,"NA":5411},{"trials":5398,"activeCount":99},[],{"trials":5400,"activeCount":99},[],{"trials":5402,"activeCount":99},[5403],{"nctId":5377,"briefTitle":5378,"status":107,"phases":5404,"primaryCompletion":5380,"completion":5380,"start":5381,"enrollment":5382,"conditions":5405,"interventions":5406},[88],[5384,5385,5386],[5368,5388],{"trials":5408,"activeCount":99},[],{"trials":5410,"activeCount":99},[],{"trials":5412,"activeCount":99},[],{"intervention":5414,"totalTrials":219,"cells":5415},"FLT3 Ligand Therapy",{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5417,"activeCount":99},[],{"trials":5419,"activeCount":99},[],{"trials":5421,"activeCount":99},[5422],{"nctId":5423,"briefTitle":5424,"status":107,"phases":5425,"primaryCompletion":5426,"completion":5427,"start":5284,"enrollment":943,"conditions":5428,"interventions":5430},"NCT02839265","FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer",[88],"2022-10-05","2024-11-22",[5429],"Non-small Cell Lung Cancer (NSCLC)",[5414],{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"intervention":5438,"totalTrials":219,"cells":5439},"Liposomal Bupivacaine TAP block",{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5441,"activeCount":99},[],{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":99},[5446],{"nctId":5447,"briefTitle":5448,"status":107,"phases":5449,"primaryCompletion":5450,"completion":1788,"start":5451,"enrollment":5452,"conditions":5453,"interventions":5455},"NCT03373591","Liposomal Bupivacaine in Bariatric Surgery",[88],"2018-06-30","2018-01-30",219,[5454],"Bariatric Surgery Analgesia",[5438,5456],"Bupivacaine TAP block",{"trials":5458,"activeCount":99},[],{"trials":5460,"activeCount":99},[],{"trials":5462,"activeCount":99},[],{"intervention":5456,"totalTrials":219,"cells":5464},{"EARLY_PHASE1":5465,"PHASE1":5467,"PHASE2":5469,"PHASE3":5475,"PHASE4":5477,"NA":5479},{"trials":5466,"activeCount":99},[],{"trials":5468,"activeCount":99},[],{"trials":5470,"activeCount":99},[5471],{"nctId":5447,"briefTitle":5448,"status":107,"phases":5472,"primaryCompletion":5450,"completion":1788,"start":5451,"enrollment":5452,"conditions":5473,"interventions":5474},[88],[5454],[5438,5456],{"trials":5476,"activeCount":99},[],{"trials":5478,"activeCount":99},[],{"trials":5480,"activeCount":99},[],{"intervention":5482,"totalTrials":219,"cells":5483},"Cantharidin",{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5499,"PHASE4":5501,"NA":5503},{"trials":5485,"activeCount":99},[],{"trials":5487,"activeCount":99},[],{"trials":5489,"activeCount":99},[5490],{"nctId":5491,"briefTitle":5492,"status":107,"phases":5493,"primaryCompletion":5494,"completion":5332,"start":5495,"enrollment":1289,"conditions":5496,"interventions":5498},"NCT02665260","Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum",[88],"2015-11","2012-07",[5497],"Molluscum Contagiosum",[5482],{"trials":5500,"activeCount":99},[],{"trials":5502,"activeCount":99},[],{"trials":5504,"activeCount":99},[],{"intervention":5506,"totalTrials":398,"cells":5507},"Paclitaxel",{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5535,"PHASE3":5537,"PHASE4":5539,"NA":5541},{"trials":5509,"activeCount":99},[],{"trials":5511,"activeCount":99},[5512,5525],{"nctId":5513,"briefTitle":5514,"status":257,"phases":5515,"primaryCompletion":5516,"completion":5516,"start":5284,"enrollment":1813,"conditions":5517,"interventions":5522},"NCT02824575","Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer",[87],"2021-12-27",[29,5518,5519,5520,5521],"Breast Adenocarcinoma","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Recurrent Breast Carcinoma","Stage IV Breast Cancer",[5523,5506,5524],"Rebastinib","Eribulin Mesylate",{"nctId":5526,"briefTitle":5527,"status":107,"phases":5528,"primaryCompletion":5529,"completion":5529,"start":5530,"enrollment":3409,"conditions":5531,"interventions":5532},"NCT00004863","Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors",[87],"2001-08","1999-07",[4439],[5533,5534],"GEM 231","paclitaxel",{"trials":5536,"activeCount":99},[],{"trials":5538,"activeCount":99},[],{"trials":5540,"activeCount":99},[],{"trials":5542,"activeCount":99},[],{"intervention":5533,"totalTrials":398,"cells":5544},{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5561,"PHASE3":5563,"PHASE4":5565,"NA":5567},{"trials":5546,"activeCount":99},[],{"trials":5548,"activeCount":99},[5549,5557],{"nctId":5550,"briefTitle":5551,"status":107,"phases":5552,"primaryCompletion":5553,"completion":5553,"start":5530,"conditions":5554,"interventions":5555},"NCT00004864","Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors",[87],"2000-06",[4439],[5533,5556],"docetaxel",{"nctId":5526,"briefTitle":5527,"status":107,"phases":5558,"primaryCompletion":5529,"completion":5529,"start":5530,"enrollment":3409,"conditions":5559,"interventions":5560},[87],[4439],[5533,5534],{"trials":5562,"activeCount":99},[],{"trials":5564,"activeCount":99},[],{"trials":5566,"activeCount":99},[],{"trials":5568,"activeCount":99},[],{"intervention":5523,"totalTrials":219,"cells":5570},{"EARLY_PHASE1":5571,"PHASE1":5573,"PHASE2":5579,"PHASE3":5581,"PHASE4":5583,"NA":5585},{"trials":5572,"activeCount":99},[],{"trials":5574,"activeCount":99},[5575],{"nctId":5513,"briefTitle":5514,"status":257,"phases":5576,"primaryCompletion":5516,"completion":5516,"start":5284,"enrollment":1813,"conditions":5577,"interventions":5578},[87],[29,5518,5519,5520,5521],[5523,5506,5524],{"trials":5580,"activeCount":99},[],{"trials":5582,"activeCount":99},[],{"trials":5584,"activeCount":99},[],{"trials":5586,"activeCount":99},[],{"intervention":5524,"totalTrials":219,"cells":5588},{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5597,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5590,"activeCount":99},[],{"trials":5592,"activeCount":99},[5593],{"nctId":5513,"briefTitle":5514,"status":257,"phases":5594,"primaryCompletion":5516,"completion":5516,"start":5284,"enrollment":1813,"conditions":5595,"interventions":5596},[87],[29,5518,5519,5520,5521],[5523,5506,5524],{"trials":5598,"activeCount":99},[],{"trials":5600,"activeCount":99},[],{"trials":5602,"activeCount":99},[],{"trials":5604,"activeCount":99},[],{"intervention":5606,"totalTrials":219,"cells":5607},"capecitabine",{"EARLY_PHASE1":5608,"PHASE1":5610,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5609,"activeCount":99},[],{"trials":5611,"activeCount":99},[5612],{"nctId":5613,"briefTitle":5614,"status":107,"phases":5615,"primaryCompletion":4437,"completion":4437,"start":5616,"enrollment":4413,"conditions":5617,"interventions":5618},"NCT00003867","Irinotecan and Capecitabine in Treating Patients With Solid Tumors",[87],"1999-03",[4639],[5606,5619],"irinotecan hydrochloride",{"trials":5621,"activeCount":99},[],{"trials":5623,"activeCount":99},[],{"trials":5625,"activeCount":99},[],{"trials":5627,"activeCount":99},[],{"intervention":5619,"totalTrials":219,"cells":5629},{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5638,"PHASE3":5640,"PHASE4":5642,"NA":5644},{"trials":5631,"activeCount":99},[],{"trials":5633,"activeCount":99},[5634],{"nctId":5613,"briefTitle":5614,"status":107,"phases":5635,"primaryCompletion":4437,"completion":4437,"start":5616,"enrollment":4413,"conditions":5636,"interventions":5637},[87],[4639],[5606,5619],{"trials":5639,"activeCount":99},[],{"trials":5641,"activeCount":99},[],{"trials":5643,"activeCount":99},[],{"trials":5645,"activeCount":99},[],{"intervention":5556,"totalTrials":219,"cells":5647},{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5656,"PHASE3":5658,"PHASE4":5660,"NA":5662},{"trials":5649,"activeCount":99},[],{"trials":5651,"activeCount":99},[5652],{"nctId":5550,"briefTitle":5551,"status":107,"phases":5653,"primaryCompletion":5553,"completion":5553,"start":5530,"conditions":5654,"interventions":5655},[87],[4439],[5533,5556],{"trials":5657,"activeCount":99},[],{"trials":5659,"activeCount":99},[],{"trials":5661,"activeCount":99},[],{"trials":5663,"activeCount":99},[],{"intervention":5665,"totalTrials":219,"cells":5666},"Pyrimethamine",{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5678,"PHASE3":5680,"PHASE4":5682,"NA":5684},{"trials":5668,"activeCount":99},[],{"trials":5670,"activeCount":99},[5671],{"nctId":5672,"briefTitle":5673,"status":800,"phases":5674,"primaryCompletion":5675,"completion":5675,"start":5381,"enrollment":99,"conditions":5676,"interventions":5677},"NCT03057990","Pyrimethamine for Intermediate\u002FHigh-risk Myelodysplastic Syndromes (MDS)",[87],"2021-06-29",[956],[5665],{"trials":5679,"activeCount":99},[],{"trials":5681,"activeCount":99},[],{"trials":5683,"activeCount":99},[],{"trials":5685,"activeCount":99},[],{"intervention":5687,"totalTrials":219,"cells":5688},"Trichuris Suis Ova",{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5699,"PHASE3":5701,"PHASE4":5703,"NA":5705},{"trials":5690,"activeCount":99},[],{"trials":5692,"activeCount":99},[5693],{"nctId":5694,"briefTitle":5695,"status":107,"phases":5696,"primaryCompletion":2573,"completion":2256,"start":190,"enrollment":95,"conditions":5697,"interventions":5698},"NCT01040221","Trichuris Suis Ova in Autism Spectrum Disorders",[87],[3010],[5687],{"trials":5700,"activeCount":99},[],{"trials":5702,"activeCount":99},[],{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"intervention":4441,"totalTrials":219,"cells":5708},{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5717,"PHASE3":5719,"PHASE4":5721,"NA":5723},{"trials":5710,"activeCount":99},[],{"trials":5712,"activeCount":99},[5713],{"nctId":4433,"briefTitle":4434,"status":107,"phases":5714,"primaryCompletion":4436,"completion":4436,"start":4437,"enrollment":9,"conditions":5715,"interventions":5716},[87],[4439],[4426,4441],{"trials":5718,"activeCount":99},[],{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[],{"intervention":5726,"totalTrials":219,"cells":5727},"enalapril",{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5740,"PHASE3":5742,"PHASE4":5744,"NA":5746},{"trials":5729,"activeCount":99},[],{"trials":5731,"activeCount":99},[5732],{"nctId":5733,"briefTitle":5734,"status":107,"phases":5735,"primaryCompletion":3407,"completion":3407,"start":5736,"enrollment":5382,"conditions":5737,"interventions":5739},"NCT00270153","The Use of ACE Inhibitors in the Early Renal Post-transplant Period",[87],"2004-09",[5738],"Renal Transplant",[5726],{"trials":5741,"activeCount":99},[],{"trials":5743,"activeCount":99},[],{"trials":5745,"activeCount":99},[],{"trials":5747,"activeCount":99},[],{"intervention":5749,"totalTrials":219,"cells":5750},"Gemcitabine + Cisplatin",{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5766,"PHASE3":5768,"PHASE4":5770,"NA":5772},{"trials":5752,"activeCount":99},[],{"trials":5754,"activeCount":99},[5755],{"nctId":5756,"briefTitle":5757,"status":107,"phases":5758,"primaryCompletion":5759,"completion":5759,"start":4494,"enrollment":5760,"conditions":5761,"interventions":5762},"NCT03403049","Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer",[87],"2019-07-09",14,[267,4639],[5749,5763,5764,5765],"Gemcitabine + Capecitabine","Gemcitabine + Erlotinib","Gemcitabine",{"trials":5767,"activeCount":99},[],{"trials":5769,"activeCount":99},[],{"trials":5771,"activeCount":99},[],{"trials":5773,"activeCount":99},[],{"intervention":5763,"totalTrials":219,"cells":5775},{"EARLY_PHASE1":5776,"PHASE1":5778,"PHASE2":5784,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5777,"activeCount":99},[],{"trials":5779,"activeCount":99},[5780],{"nctId":5756,"briefTitle":5757,"status":107,"phases":5781,"primaryCompletion":5759,"completion":5759,"start":4494,"enrollment":5760,"conditions":5782,"interventions":5783},[87],[267,4639],[5749,5763,5764,5765],{"trials":5785,"activeCount":99},[],{"trials":5787,"activeCount":99},[],{"trials":5789,"activeCount":99},[],{"trials":5791,"activeCount":99},[],{"intervention":5764,"totalTrials":219,"cells":5793},{"EARLY_PHASE1":5794,"PHASE1":5796,"PHASE2":5802,"PHASE3":5804,"PHASE4":5806,"NA":5808},{"trials":5795,"activeCount":99},[],{"trials":5797,"activeCount":99},[5798],{"nctId":5756,"briefTitle":5757,"status":107,"phases":5799,"primaryCompletion":5759,"completion":5759,"start":4494,"enrollment":5760,"conditions":5800,"interventions":5801},[87],[267,4639],[5749,5763,5764,5765],{"trials":5803,"activeCount":99},[],{"trials":5805,"activeCount":99},[],{"trials":5807,"activeCount":99},[],{"trials":5809,"activeCount":99},[],{"intervention":5765,"totalTrials":219,"cells":5811},{"EARLY_PHASE1":5812,"PHASE1":5814,"PHASE2":5820,"PHASE3":5822,"PHASE4":5824,"NA":5826},{"trials":5813,"activeCount":99},[],{"trials":5815,"activeCount":99},[5816],{"nctId":5756,"briefTitle":5757,"status":107,"phases":5817,"primaryCompletion":5759,"completion":5759,"start":4494,"enrollment":5760,"conditions":5818,"interventions":5819},[87],[267,4639],[5749,5763,5764,5765],{"trials":5821,"activeCount":99},[],{"trials":5823,"activeCount":99},[],{"trials":5825,"activeCount":99},[],{"trials":5827,"activeCount":99},[],{"intervention":5829,"totalTrials":219,"cells":5830},"Regional Anesthetics",{"EARLY_PHASE1":5831,"PHASE1":5844,"PHASE2":5846,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5832,"activeCount":99},[5833],{"nctId":5834,"briefTitle":5835,"status":800,"phases":5836,"primaryCompletion":5837,"completion":5837,"start":5838,"enrollment":99,"conditions":5839,"interventions":5843},"NCT04335461","Postop Pain Control in Hip Fracture Surgery: Fascia Iliaca Compartment Block Versus Fracture Block",[86],"2023-03-17","2021-08-05",[5840,5841,5842,282],"Hip Fractures","Analgesia","Opioid Use",[5829],{"trials":5845,"activeCount":99},[],{"trials":5847,"activeCount":99},[],{"trials":5849,"activeCount":99},[],{"trials":5851,"activeCount":99},[],{"trials":5853,"activeCount":99},[],{"intervention":2104,"totalTrials":219,"cells":5855},{"EARLY_PHASE1":5856,"PHASE1":5862,"PHASE2":5864,"PHASE3":5866,"PHASE4":5868,"NA":5870},{"trials":5857,"activeCount":99},[5858],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5859,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5860,"interventions":5861},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5863,"activeCount":99},[],{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":99},[],{"trials":5869,"activeCount":99},[],{"trials":5871,"activeCount":99},[],{"intervention":2105,"totalTrials":219,"cells":5873},{"EARLY_PHASE1":5874,"PHASE1":5880,"PHASE2":5882,"PHASE3":5884,"PHASE4":5886,"NA":5888},{"trials":5875,"activeCount":99},[5876],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5877,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5878,"interventions":5879},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[],{"trials":5885,"activeCount":99},[],{"trials":5887,"activeCount":99},[],{"trials":5889,"activeCount":99},[],{"intervention":2106,"totalTrials":219,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5898,"PHASE2":5900,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5893,"activeCount":99},[5894],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5895,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5896,"interventions":5897},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5899,"activeCount":99},[],{"trials":5901,"activeCount":99},[],{"trials":5903,"activeCount":99},[],{"trials":5905,"activeCount":99},[],{"trials":5907,"activeCount":99},[],{"intervention":2108,"totalTrials":219,"cells":5909},{"EARLY_PHASE1":5910,"PHASE1":5916,"PHASE2":5918,"PHASE3":5920,"PHASE4":5922,"NA":5924},{"trials":5911,"activeCount":99},[5912],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5913,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5914,"interventions":5915},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5917,"activeCount":99},[],{"trials":5919,"activeCount":99},[],{"trials":5921,"activeCount":99},[],{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":99},[],{"intervention":2109,"totalTrials":219,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5934,"PHASE2":5936,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5929,"activeCount":99},[5930],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5931,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5932,"interventions":5933},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5935,"activeCount":99},[],{"trials":5937,"activeCount":99},[],{"trials":5939,"activeCount":99},[],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"intervention":2111,"totalTrials":219,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5952,"PHASE2":5954,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5947,"activeCount":99},[5948],{"nctId":2094,"briefTitle":2095,"status":257,"phases":5949,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":5950,"interventions":5951},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":5953,"activeCount":99},[],{"trials":5955,"activeCount":99},[],{"trials":5957,"activeCount":99},[],{"trials":5959,"activeCount":99},[],{"trials":5961,"activeCount":99},[],{"intervention":5963,"totalTrials":219,"cells":5964},"Antiarrhythmic medications",{"EARLY_PHASE1":5965,"PHASE1":5976,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5984},{"trials":5966,"activeCount":99},[5967],{"nctId":5968,"briefTitle":5969,"status":800,"phases":5970,"primaryCompletion":5971,"completion":5971,"start":5972,"enrollment":99,"conditions":5973,"interventions":5975},"NCT04512911","Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy",[86],"2023-01-23","2023-01",[5974],"Ventricular Tachycardia",[5963],{"trials":5977,"activeCount":99},[],{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[],{"trials":5983,"activeCount":99},[],{"trials":5985,"activeCount":99},[],{"intervention":299,"totalTrials":930,"cells":5987},{"EARLY_PHASE1":5988,"PHASE1":5990,"PHASE2":5992,"PHASE3":6003,"PHASE4":6005,"NA":6011},{"trials":5989,"activeCount":99},[],{"trials":5991,"activeCount":99},[],{"trials":5993,"activeCount":99},[5994],{"nctId":5995,"briefTitle":5996,"status":107,"phases":5997,"primaryCompletion":5998,"completion":5998,"start":180,"enrollment":2466,"conditions":5999,"interventions":6002},"NCT04051684","Regional TAP Block for Bariatric Patients",[87,88],"2013-05",[6000,6001],"Bariatric Surgery","Transverse Abdominal Plane Regional Blocks",[299],{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":99},[6007],{"nctId":289,"briefTitle":290,"status":107,"phases":6008,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":6009,"interventions":6010},[90],[297],[299,300,164],{"trials":6012,"activeCount":99},[6013],{"nctId":6014,"briefTitle":6015,"status":257,"phases":6016,"primaryCompletion":6017,"completion":6017,"start":6018,"enrollment":6019,"conditions":6020,"interventions":6023},"NCT03801863","The Use of Lumbar Erector Spinae Plane Block for Hip Arthroplasty at the L4 Interspace",[],"2022-01-26","2019-03-01",65,[6021,6022],"Hip Arthropathy","Regional Anesthesia",[299],{"intervention":6025,"totalTrials":930,"cells":6026},"Intranasal Oxytocin",{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6052,"PHASE4":6054,"NA":6056},{"trials":6028,"activeCount":99},[],{"trials":6030,"activeCount":99},[],{"trials":6032,"activeCount":99},[6033,6042],{"nctId":6034,"briefTitle":6035,"status":107,"phases":6036,"primaryCompletion":4049,"completion":6037,"start":3907,"enrollment":2466,"conditions":6038,"interventions":6041},"NCT02629991","Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome",[88],"2018-05",[6039,6040],"Prader-Willi Syndrome","Hyperphagia",[6025],{"nctId":6043,"briefTitle":6044,"status":257,"phases":6045,"primaryCompletion":6046,"completion":6047,"start":6048,"enrollment":27,"conditions":6049,"interventions":6051},"NCT02127073","Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer",[88],"2017-01-18","2017-09-18","2015-01-30",[29,6050],"Ductal Carcinoma in Situ",[6025],{"trials":6053,"activeCount":99},[],{"trials":6055,"activeCount":99},[],{"trials":6057,"activeCount":99},[6058],{"nctId":6059,"briefTitle":6060,"status":107,"phases":6061,"primaryCompletion":6062,"completion":6062,"start":6063,"enrollment":6064,"conditions":6065,"interventions":6067},"NCT01337687","Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders",[91],"2013-12","2009-10",19,[6066],"Autism Spectrum Disorders",[6025],{"intervention":6069,"totalTrials":398,"cells":6070},"oxytocin",{"EARLY_PHASE1":6071,"PHASE1":6073,"PHASE2":6075,"PHASE3":6077,"PHASE4":6079,"NA":6081},{"trials":6072,"activeCount":99},[],{"trials":6074,"activeCount":99},[],{"trials":6076,"activeCount":99},[],{"trials":6078,"activeCount":99},[],{"trials":6080,"activeCount":99},[],{"trials":6082,"activeCount":99},[6083,6094],{"nctId":6084,"briefTitle":6085,"status":257,"phases":6086,"primaryCompletion":3659,"completion":3659,"start":6087,"enrollment":2984,"conditions":6088,"interventions":6092},"NCT04004845","Labor Protocol Study",[],"2021-03-30",[6089,6090,6091],"Vaginal Delivery","Labor","Induced; Birth",[6093,6069],"Cytotec",{"nctId":1497,"briefTitle":1498,"status":107,"phases":6095,"primaryCompletion":1500,"completion":1500,"start":1501,"enrollment":1502,"conditions":6096,"interventions":6097},[91],[1504,1505,1506,1507],[1293,1509],{"intervention":1794,"totalTrials":398,"cells":6099},{"EARLY_PHASE1":6100,"PHASE1":6102,"PHASE2":6104,"PHASE3":6110,"PHASE4":6112,"NA":6114},{"trials":6101,"activeCount":99},[],{"trials":6103,"activeCount":99},[],{"trials":6105,"activeCount":99},[6106],{"nctId":1784,"briefTitle":1785,"status":257,"phases":6107,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":6108,"interventions":6109},[88],[1792],[1766,1607,1794,1795],{"trials":6111,"activeCount":99},[],{"trials":6113,"activeCount":99},[],{"trials":6115,"activeCount":99},[6116],{"nctId":6117,"briefTitle":6118,"status":800,"phases":6119,"primaryCompletion":3789,"completion":6120,"start":2060,"enrollment":99,"conditions":6121,"interventions":6123},"NCT03009877","Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask",[91],"2019-12",[6122],"Obesity, Morbid",[6124,6125,1794,6126],"Rocuronium","Propofol","Midazolam",{"intervention":2110,"totalTrials":398,"cells":6128},{"EARLY_PHASE1":6129,"PHASE1":6135,"PHASE2":6137,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6130,"activeCount":99},[6131],{"nctId":2094,"briefTitle":2095,"status":257,"phases":6132,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":219,"conditions":6133,"interventions":6134},[86],[2100,2101,2102],[2104,2105,2106,2107,2108,2109,2110,2111,2089],{"trials":6136,"activeCount":99},[],{"trials":6138,"activeCount":99},[],{"trials":6140,"activeCount":99},[],{"trials":6142,"activeCount":99},[],{"trials":6144,"activeCount":99},[6145],{"nctId":6146,"briefTitle":6147,"status":257,"phases":6148,"primaryCompletion":6149,"completion":6149,"start":6150,"enrollment":398,"conditions":6151,"interventions":6154},"NCT01473732","Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity",[91],"2012-08","2012-03",[6152,6153],"Chronic Allograft Injury","Calcineurin Inhibitor Toxicity",[6155,2110,6156],"Everolimus","Mycophenolic acid",{"intervention":6158,"totalTrials":398,"cells":6159},"Desmopressin",{"EARLY_PHASE1":6160,"PHASE1":6162,"PHASE2":6164,"PHASE3":6166,"PHASE4":6168,"NA":6179},{"trials":6161,"activeCount":99},[],{"trials":6163,"activeCount":99},[],{"trials":6165,"activeCount":99},[],{"trials":6167,"activeCount":99},[],{"trials":6169,"activeCount":99},[6170],{"nctId":6171,"briefTitle":6172,"status":257,"phases":6173,"primaryCompletion":6174,"completion":6174,"start":6175,"enrollment":27,"conditions":6176,"interventions":6178},"NCT04420585","Desmopressin for Bedwetting in Children With SCD",[90],"2023-06-12","2020-07-07",[6177,1938],"Nocturnal Enuresis",[6158],{"trials":6180,"activeCount":99},[6181],{"nctId":6182,"briefTitle":6183,"status":257,"phases":6184,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":5760,"conditions":6187,"interventions":6188},"NCT02636387","Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease",[],"2018-10-27","2015-08-26",[6177,1938],[6158],{"intervention":6190,"totalTrials":219,"cells":6191},"Any oral opioid",{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6198,"PHASE4":6200,"NA":6202},{"trials":6193,"activeCount":99},[],{"trials":6195,"activeCount":99},[],{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"trials":6201,"activeCount":99},[],{"trials":6203,"activeCount":99},[6204],{"nctId":6205,"briefTitle":6206,"status":107,"phases":6207,"primaryCompletion":1586,"completion":1586,"start":6208,"enrollment":6209,"conditions":6210,"interventions":6211},"NCT03375645","Montefiore Opioid and Pain Study",[],"2017-11-08",462,[21],[6190],{"intervention":6213,"totalTrials":219,"cells":6214},"Atorvastatin 80 Mg Oral",{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6219,"PHASE3":6221,"PHASE4":6223,"NA":6225},{"trials":6216,"activeCount":99},[],{"trials":6218,"activeCount":99},[],{"trials":6220,"activeCount":99},[],{"trials":6222,"activeCount":99},[],{"trials":6224,"activeCount":99},[],{"trials":6226,"activeCount":99},[6227],{"nctId":6228,"briefTitle":6229,"status":800,"phases":6230,"primaryCompletion":6231,"completion":6231,"start":6232,"enrollment":99,"conditions":6233,"interventions":6235},"NCT05251129","Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation",[91],"2030-06","2025-01",[6234],"Vasculopathy",[6213,6236],"Pravastatin 40 Mg Oral",{"intervention":6236,"totalTrials":219,"cells":6238},{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6243,"PHASE3":6245,"PHASE4":6247,"NA":6249},{"trials":6240,"activeCount":99},[],{"trials":6242,"activeCount":99},[],{"trials":6244,"activeCount":99},[],{"trials":6246,"activeCount":99},[],{"trials":6248,"activeCount":99},[],{"trials":6250,"activeCount":99},[6251],{"nctId":6228,"briefTitle":6229,"status":800,"phases":6252,"primaryCompletion":6231,"completion":6231,"start":6232,"enrollment":99,"conditions":6253,"interventions":6254},[91],[6234],[6213,6236],{"intervention":6093,"totalTrials":219,"cells":6256},{"EARLY_PHASE1":6257,"PHASE1":6259,"PHASE2":6261,"PHASE3":6263,"PHASE4":6265,"NA":6267},{"trials":6258,"activeCount":99},[],{"trials":6260,"activeCount":99},[],{"trials":6262,"activeCount":99},[],{"trials":6264,"activeCount":99},[],{"trials":6266,"activeCount":99},[],{"trials":6268,"activeCount":99},[6269],{"nctId":6084,"briefTitle":6085,"status":257,"phases":6270,"primaryCompletion":3659,"completion":3659,"start":6087,"enrollment":2984,"conditions":6271,"interventions":6272},[],[6089,6090,6091],[6093,6069],{"intervention":6124,"totalTrials":219,"cells":6274},{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6281,"PHASE4":6283,"NA":6285},{"trials":6276,"activeCount":99},[],{"trials":6278,"activeCount":99},[],{"trials":6280,"activeCount":99},[],{"trials":6282,"activeCount":99},[],{"trials":6284,"activeCount":99},[],{"trials":6286,"activeCount":99},[6287],{"nctId":6117,"briefTitle":6118,"status":800,"phases":6288,"primaryCompletion":3789,"completion":6120,"start":2060,"enrollment":99,"conditions":6289,"interventions":6290},[91],[6122],[6124,6125,1794,6126],{"intervention":6125,"totalTrials":219,"cells":6292},{"EARLY_PHASE1":6293,"PHASE1":6295,"PHASE2":6297,"PHASE3":6299,"PHASE4":6301,"NA":6303},{"trials":6294,"activeCount":99},[],{"trials":6296,"activeCount":99},[],{"trials":6298,"activeCount":99},[],{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":99},[],{"trials":6304,"activeCount":99},[6305],{"nctId":6117,"briefTitle":6118,"status":800,"phases":6306,"primaryCompletion":3789,"completion":6120,"start":2060,"enrollment":99,"conditions":6307,"interventions":6308},[91],[6122],[6124,6125,1794,6126],{"intervention":6126,"totalTrials":219,"cells":6310},{"EARLY_PHASE1":6311,"PHASE1":6313,"PHASE2":6315,"PHASE3":6317,"PHASE4":6319,"NA":6321},{"trials":6312,"activeCount":99},[],{"trials":6314,"activeCount":99},[],{"trials":6316,"activeCount":99},[],{"trials":6318,"activeCount":99},[],{"trials":6320,"activeCount":99},[],{"trials":6322,"activeCount":99},[6323],{"nctId":6117,"briefTitle":6118,"status":800,"phases":6324,"primaryCompletion":3789,"completion":6120,"start":2060,"enrollment":99,"conditions":6325,"interventions":6326},[91],[6122],[6124,6125,1794,6126],{"intervention":6155,"totalTrials":219,"cells":6328},{"EARLY_PHASE1":6329,"PHASE1":6331,"PHASE2":6333,"PHASE3":6335,"PHASE4":6337,"NA":6339},{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[],{"trials":6334,"activeCount":99},[],{"trials":6336,"activeCount":99},[],{"trials":6338,"activeCount":99},[],{"trials":6340,"activeCount":99},[6341],{"nctId":6146,"briefTitle":6147,"status":257,"phases":6342,"primaryCompletion":6149,"completion":6149,"start":6150,"enrollment":398,"conditions":6343,"interventions":6344},[91],[6152,6153],[6155,2110,6156],{"intervention":6156,"totalTrials":219,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6348,"activeCount":99},[],{"trials":6350,"activeCount":99},[],{"trials":6352,"activeCount":99},[],{"trials":6354,"activeCount":99},[],{"trials":6356,"activeCount":99},[],{"trials":6358,"activeCount":99},[6359],{"nctId":6146,"briefTitle":6147,"status":257,"phases":6360,"primaryCompletion":6149,"completion":6149,"start":6150,"enrollment":398,"conditions":6361,"interventions":6362},[91],[6152,6153],[6155,2110,6156],{"intervention":6364,"totalTrials":219,"cells":6365},"Nicotine polacrilex",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6374,"NA":6376},{"trials":6367,"activeCount":99},[],{"trials":6369,"activeCount":99},[],{"trials":6371,"activeCount":99},[],{"trials":6373,"activeCount":99},[],{"trials":6375,"activeCount":99},[],{"trials":6377,"activeCount":99},[6378],{"nctId":6379,"briefTitle":6380,"status":107,"phases":6381,"primaryCompletion":6382,"completion":6382,"start":6383,"enrollment":6384,"conditions":6385,"interventions":6388},"NCT02781090","RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers",[91],"2020-09-14","2016-07-06",512,[6386,6387],"Tobacco Use Disorder","HIV",[6364],{"intervention":6390,"totalTrials":219,"cells":6391},"Iohexol",{"EARLY_PHASE1":6392,"PHASE1":6394,"PHASE2":6396,"PHASE3":6398,"PHASE4":6400,"NA":6402},{"trials":6393,"activeCount":99},[],{"trials":6395,"activeCount":99},[],{"trials":6397,"activeCount":99},[],{"trials":6399,"activeCount":99},[],{"trials":6401,"activeCount":99},[],{"trials":6403,"activeCount":99},[6404],{"nctId":6405,"briefTitle":6406,"status":107,"phases":6407,"primaryCompletion":6408,"completion":6409,"start":6410,"enrollment":379,"conditions":6411,"interventions":6413},"NCT04582500","Virtual Colonoscopy Using Omnipaque as a Contrast Agent",[],"2024-03-14","2025-03-31","2021-02-15",[6412],"Colorectal Cancer",[6390],{"intervention":6415,"totalTrials":219,"cells":6416},"PCV15",{"EARLY_PHASE1":6417,"PHASE1":6419,"PHASE2":6421,"PHASE3":6423,"PHASE4":6425,"NA":6427},{"trials":6418,"activeCount":99},[],{"trials":6420,"activeCount":99},[],{"trials":6422,"activeCount":99},[],{"trials":6424,"activeCount":99},[],{"trials":6426,"activeCount":99},[],{"trials":6428,"activeCount":99},[6429],{"nctId":6430,"briefTitle":6431,"status":257,"phases":6432,"primaryCompletion":6433,"completion":6433,"start":6434,"enrollment":1457,"conditions":6435,"interventions":6437},"NCT04845945","MISP 60528 Pneumococcal Vaccination",[],"2024-08-24","2021-06-10",[6436],"Heart Transplant Infection Prevention",[6415],{"intervention":6439,"totalTrials":219,"cells":6440},"Morphine 0.1mg\u002Fkg versus morphine 0.15 mg\u002Fkg",{"EARLY_PHASE1":6441,"PHASE1":6443,"PHASE2":6445,"PHASE3":6447,"PHASE4":6449,"NA":6451},{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[],{"trials":6446,"activeCount":99},[],{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":99},[6453],{"nctId":6454,"briefTitle":6455,"status":107,"phases":6456,"completion":4762,"start":6457,"enrollment":6458,"conditions":6459,"interventions":6460},"NCT00293969","A Trial Comparing Different Dosing Regimens of Morphine in Patients With Moderate to Severe Pain",[91],"2005-03",280,[18],[6439],{"intervention":6462,"totalTrials":219,"cells":6463},"Pasireotide",{"EARLY_PHASE1":6464,"PHASE1":6466,"PHASE2":6468,"PHASE3":6470,"PHASE4":6472,"NA":6474},{"trials":6465,"activeCount":99},[],{"trials":6467,"activeCount":99},[],{"trials":6469,"activeCount":99},[],{"trials":6471,"activeCount":99},[],{"trials":6473,"activeCount":99},[],{"trials":6475,"activeCount":99},[6476],{"nctId":6477,"briefTitle":6478,"status":6479,"phases":6480,"conditions":6481,"interventions":6482},"NCT02835131","Compassionate Use of SOM230 for Hyperinsulinemic\u002FHypoglycemia","NO_LONGER_AVAILABLE",[],[5224],[6462],{"intervention":6484,"totalTrials":219,"cells":6485},"HEMLIBRA",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6490,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6487,"activeCount":99},[],{"trials":6489,"activeCount":99},[],{"trials":6491,"activeCount":99},[],{"trials":6493,"activeCount":99},[],{"trials":6495,"activeCount":99},[],{"trials":6497,"activeCount":99},[6498],{"nctId":6499,"briefTitle":6500,"status":107,"phases":6501,"primaryCompletion":6502,"completion":6502,"start":6503,"enrollment":4563,"conditions":6504,"interventions":6506},"NCT05248594","Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A",[],"2025-07-18","2024-08-01",[6505],"Hemophilia A",[6484],{"intervention":6508,"totalTrials":219,"cells":6509},"Cinacalcet",{"EARLY_PHASE1":6510,"PHASE1":6512,"PHASE2":6514,"PHASE3":6516,"PHASE4":6518,"NA":6520},{"trials":6511,"activeCount":99},[],{"trials":6513,"activeCount":99},[],{"trials":6515,"activeCount":99},[],{"trials":6517,"activeCount":99},[],{"trials":6519,"activeCount":99},[],{"trials":6521,"activeCount":99},[6522],{"nctId":6523,"briefTitle":6524,"status":257,"phases":6525,"primaryCompletion":6526,"completion":6526,"start":191,"enrollment":753,"conditions":6527,"interventions":6529},"NCT01011114","Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant",[91],"2015-10-15",[6528,5738],"Hypophosphatemia",[6508],{"intervention":6531,"totalTrials":219,"cells":6532},"Iodine povidone",{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6539,"PHASE4":6541,"NA":6543},{"trials":6534,"activeCount":99},[],{"trials":6536,"activeCount":99},[],{"trials":6538,"activeCount":99},[],{"trials":6540,"activeCount":99},[],{"trials":6542,"activeCount":99},[],{"trials":6544,"activeCount":99},[6545],{"nctId":6546,"briefTitle":6547,"status":107,"phases":6548,"primaryCompletion":2256,"completion":2256,"start":3730,"enrollment":6549,"conditions":6550,"interventions":6552},"NCT01870583","Comparison of Surgical Skin Preps During Cesarean Deliveries",[91],1404,[6551],"Surgical Site Infection Following Cesarean Delivery",[6531,6553,6554],"Chlorhexidine","Combination iodine and chlorhexidine",{"intervention":6553,"totalTrials":219,"cells":6556},{"EARLY_PHASE1":6557,"PHASE1":6559,"PHASE2":6561,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6558,"activeCount":99},[],{"trials":6560,"activeCount":99},[],{"trials":6562,"activeCount":99},[],{"trials":6564,"activeCount":99},[],{"trials":6566,"activeCount":99},[],{"trials":6568,"activeCount":99},[6569],{"nctId":6546,"briefTitle":6547,"status":107,"phases":6570,"primaryCompletion":2256,"completion":2256,"start":3730,"enrollment":6549,"conditions":6571,"interventions":6572},[91],[6551],[6531,6553,6554],{"intervention":6554,"totalTrials":219,"cells":6574},{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6579,"PHASE3":6581,"PHASE4":6583,"NA":6585},{"trials":6576,"activeCount":99},[],{"trials":6578,"activeCount":99},[],{"trials":6580,"activeCount":99},[],{"trials":6582,"activeCount":99},[],{"trials":6584,"activeCount":99},[],{"trials":6586,"activeCount":99},[6587],{"nctId":6546,"briefTitle":6547,"status":107,"phases":6588,"primaryCompletion":2256,"completion":2256,"start":3730,"enrollment":6549,"conditions":6589,"interventions":6590},[91],[6551],[6531,6553,6554],{"intervention":6592,"totalTrials":219,"cells":6593},"3% sodium chloride",{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6600,"PHASE4":6602,"NA":6604},{"trials":6595,"activeCount":99},[],{"trials":6597,"activeCount":99},[],{"trials":6599,"activeCount":99},[],{"trials":6601,"activeCount":99},[],{"trials":6603,"activeCount":99},[],{"trials":6605,"activeCount":99},[6606],{"nctId":6607,"briefTitle":6608,"status":107,"phases":6609,"primaryCompletion":2256,"completion":6610,"start":4236,"enrollment":6611,"conditions":6612,"interventions":6614},"NCT01488448","A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis",[91],"2015-08",227,[6613],"Bronchiolitis",[6592,6615],"0.9% sodium chloride",{"intervention":6615,"totalTrials":219,"cells":6617},{"EARLY_PHASE1":6618,"PHASE1":6620,"PHASE2":6622,"PHASE3":6624,"PHASE4":6626,"NA":6628},{"trials":6619,"activeCount":99},[],{"trials":6621,"activeCount":99},[],{"trials":6623,"activeCount":99},[],{"trials":6625,"activeCount":99},[],{"trials":6627,"activeCount":99},[],{"trials":6629,"activeCount":99},[6630],{"nctId":6607,"briefTitle":6608,"status":107,"phases":6631,"primaryCompletion":2256,"completion":6610,"start":4236,"enrollment":6611,"conditions":6632,"interventions":6633},[91],[6613],[6592,6615]]